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Introduction
If you want to place a winning bet, bet that heart disease will kill you. Yes,
you. Why? Because heart disease kills more people in the U.S. than any other disease,
including cancer. We want to reverse that bet and save your life. How? You need to read this
book and follow its simple recommendations. Many people have already jumped on the
bandwagon and defied the probability of dying from heart disease. This book gives you the
easy tools to do just that. Prevention costs practically nothing and you don’t have to give up
anything. You only have to eat and be smart about saving your heart.
So why is our book different from all the books, pamphlets, notices, alerts, newspaper,
magazine articles, etc., all describing heart disease in the United States?
First, in spite of all of the available therapies including bypass and stent surgery, the total
number of people with heart attacks in every town, city, and state is increasing.
Second, many books fail to mention that the individual who had the heart attack incurred a
hospital bill often in excess of half a million dollars and he/she may become a “cardiac cripple”
requiring oxygen 24 hours/day. Needless to say, that individual’s health and lifestyle has
changed from “good” to “greatly impaired.”
To put the seriousness of heart disease in perspective, the 600,000 individuals in the United
States who have a heart attack each year equals approximately one heart attack every minute
(the population of a small city). To bring these statistics closer to home, the most likely cause
of your personal demise is a heart attack secondary to disease in your heart’s arteries, not
cancer.
The third reason that we felt compelled to write this book is that there is no rational reason for
anyone to have a heart attack. The understanding and knowledge of the vessel disease that
causes a heart attack and how to prevent this catastrophic event has recently been discovered
and reported in the medical literature. Knowledge in the field of medicine has exploded,
overwhelming many conscientious physicians from keeping up to date. This is because new
knowledge has accrued from the basic sciences, animal studies, primate studies, and human
studies at an astonishing rate. To assimilate this knowledge, even for specialists in the field, is
a major challenge.
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We believe that the answer to this dilemma is to bring new information to every individual on
what that person should do to prevent heart disease in himself/herself and/or his/her family.
Reading this book will provide all the knowledge that is necessary to prevent or reverse heart
disease in the individual person at risk. We have purposely kept each chapter short – 2 pages,
including a figure illustrating each chapter’s main point. For individuals desiring more in depth
information, we have included medical references at the end of each section and at the end of
the book.

Figure legend – The authors working on chapters in the book. If you have any questions or
comments after reading this book, please contact us. Our email address is HSCendo@salud.unm.edu
Sincerely, David S. Schade, MD and R. Philip Eaton, MD
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The Authors
We thought the readers might be interested in how the authors met and why they formed a
long-term partnership. In 1973, R. Philip Eaton, MD was Chief of the Endocrinology Division in
the Department of Internal Medicine at the University of New Mexico School of Medicine.
David S. Schade, MD had just joined the Endocrine Division as a trainee. During this two-year
training period, Dr. Eaton became the mentor of Dr. Schade and provided critical information to
Dr. Schade on research techniques and endocrine patient care. A solid partnership was
formed, resulting in many advances in medicine that were important to the health of the New
Mexico population. For example, they were the first to describe the success of a totally
implantable insulin pump in diabetic patients, in collaboration with Dr. William Spencer of the
Microelectronics Division of Sandia Laboratories. They were also the scientists that proved
that subcutaneous insulin resistance was not
the cause of poor glucose control in type
one diabetes. Furthermore, they described
the importance of using low dose insulin
therapy in diabetic ketoacidosis, a potentially
lethal condition in diabetes. More recently,
they have been instrumental in efforts to
prevent heart disease in New Mexico
citizens, not only through multiple
publications in the scientific and lay press
but also at the New Mexico State legislature.
Throughout these many years of
partnership, their goal has always been to
improve the health of the New Mexico and
United States population. A short biography
of each author is given below.
Figure legend – Dr. Schade (left) and Dr.
Eaton (right) at the New Mexico State legislature supporting their bill to encourage medical
insurance companies to reimburse patients for the cost of a calcium heart scan.
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The Development of a Heart Attack
Contrary to popular belief, a heart attack doesn't just happen. In fact, it threatens to erupt for
many years before the catastrophic event occurs. Knowing how it develops is the key to
prevention. The figures/text below will provide you the "nuts and bolts" of how it happens so
you can prevent having one. This is the number one
cause of death in America today. In the United States,
every minute someone has a heart attack. Do not let it
be you!
When you were born, your arteries were clean,
smooth, and flexible pipes, through which your blood
flowed unobstructed to reach your heart and other vital
organs, i.e., your brain, lungs, kidneys, as well as your
legs and arms.
In this blood are red blood cells to carry oxygen, white blood cells to fight infection, and
platelets to stop bleeding in case you cut yourself. The inflammation and healing of cuts and
bumps like pimples can also occur in your blood vessels where they form a scab that were
named "Plaques" by physicians in the 1800's.
When you eat food like dairy products that contain cholesterol (milk, eggs, cheese, etc.), your
body needs a safe way to move the cholesterol and fat in these foods through your blood. In
response, you developed a way of "packaging" the cholesterol in your blood into tiny particles,
wrapped in protein strings called "Low Density Lipoproteins" or simply LDLc.
To keep your LDLc level in the blood normal, your body developed an ingenious solution. It
constructed specific cholesterol removers called "LDL-Receptors" on the liver. These
receptors catch the LDLc particles in your blood and excrete the cholesterol into your
gallbladder for disposal in the stool.
This approach worked very well until we started to eat “fast
food.” We are all captives of the Western diet, which
contains many foods high in cholesterol. This change
caused us to eat too much cholesterol and overwhelmed
the ability of the liver's removal system. When this
happens, the extra LDLc becomes fuel for inflammation in
the walls of our blood vessels. A high blood level of “CReactive Protein” (hsCRP) can mean vessel inflammation.
Cholesterol plaques then develop in our arteries that our
body tries to heal. This healing process sticks "flecks of calcium” around these plaques. This
is lucky, since your physician can identify these calcified plaques with a CAT scan, and
recognizes that they are the injured part of the artery that becomes a heart attack.
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The inflammation begins when you are born, driven by LDLc alone as a natural process that
accumulates each year that we live (like grey hair, i.e., a normal process of aging). However, it
is aggravated by "insults" like smoking, high blood pressure, diabetes, overweight, and other
risk factors.
This inflammation is much like any infection in your skin, similar
to a pimple containing cholesterol "pus." As it swells, it begins
to push into the flow of blood within your heart blood vessels
(coronary arteries). It gradually squeezes down the space in
these straw-like blood vessels, which makes it hard for your
heart to get oxygen from the red blood cells flowing in these
vessels.
Now your heart is in a dangerous fix. These arterial plaques
can suddenly explode into your coronary artery, causing an
obstruction. Your body immediately responds by trying to stop
the rupture by rushing plugs of platelets (similar to stopping bleeding from a cut in your skin). If
the resulting blood clot totally obstructs the flow of oxygen containing blood to your heart, you
develop the acute pain and crises that we know as a "Heart
Attack."
Preventing a heart attack is not rocket science. It involves
lowering the LDLc to the level that you were born with, and
interrupting the inflammatory machine that your age, blood
pressure, smoking, diabetes, etc. have been creating.
Other good news is that you also have a method of removing
the plaque cholesterol while it is forming called "HDL
Cholesterol" or "Good Cholesterol." It removes LDLc-derived cholesterol from the plaques in
the wall of the artery and takes it to the liver for disposal. But it too can be overwhelmed if you
don't limit your food cholesterol that you eat. That is why we say "Eat Smart and Live Long."
Finally, this story has a very exciting concluding chapter.
Science today has developed medications that help the body
processes lower your LDLc to a healthy level. How to do this
is the focus of this book. So pick a question, read the twopage answer, and "Save Your Heart."
P.S. – a more detailed explanation of events leading to a
heart attack is given in the appendix.
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What Makes
You Tick ?
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Chapter A1: The history of diffuse atherosclerosis?
Clinical Vignette
Walt Eisenhoff is a 55 year old biology teacher at a local college. He is very interested in
preventing heart disease but wonders whether he is seeing the big picture. At a recent public
lecture on cardiovascular diseases, he asked, “Can a heart attack be considered as secondary
to blood vessel disease, instead of being a disease of heart muscle? And if it can, does it
mean that other blood vessels in our bodies could have atherosclerosis and cause disease in
other organs?”
Comment
To rephrase Walt’s questions, “If a cholesterol-induced inflammation of vessels anywhere in the
body is the fundamental disease leading to an heart attack, what other organs could also
become damaged by the same process?” Historically, in 1815 the pathologist J. Hodgson first
described the fatty arterial degeneration seen in arteries in man as atheroma, from the Greek
word for porridge. Coincidently, in 1812 doctor John Warren described sudden death in
patients experiencing acute chest and neck pain and called it angina pectoris, from the Greek
words “strangling throat.” Thirty years later in 1833, the term atherosclerosis was first used by
pathologist Johann Lobstein based upon his microscopic description of blood vessel plaque
formation with fatty degeneration of cholesterol. A link between the pathologist’s description of
atherosclerosis and the doctor’s description of heart attacks was suggested.
One hundred years passed with no further major medical advances in preventing heart
disease. Finally, in 1945 the U.S. government initiated the Framingham Heart Study to look for
connections between common illnesses and the occurrence of heart attacks. The idea was to
identify any association with the proposed heart attack risks of hypertension, diabetes, blood
cholesterol, aging, or gender to actual heart attacks. During the next 40 years two scientists,
Doctors Brown and Goldstein asked whether families with inherited high blood cholesterol
levels also experienced heart attacks. After much effort, they confirmed this link and for it
received the 1985 Nobel Prize in medicine. As a result of their discovery, the search for
treating high blood cholesterol immediately began. Seven years later, Dr. Akira Endo reported
the beneficial effect of statins to block cholesterol production in the liver, which resulted in the
reduction of the occurrence of heart attacks.
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Meanwhile, the investigation of inflammation continued and in the last decade a close
association of inflammation with heart attacks was established. The cardiologist, Doctor Paul
Ridker, demonstrated that increased inflammation was as important as increased cholesterol
for the causation of heart attacks. It is now clear that stroke occurring in the brain, abdominal
aorta aneurysm, kidney failure, and vascular obstruction in legs are all diseases of
atherosclerosis in blood vessels as the primary underlying disease process.
The answer to Walt’s question has required over 200 years of research, from 1815 to the
present. Clearly, disease of the arterial vessels providing blood to the heart is the primary
cause of heart attacks. However, these diseased vessels are not restricted to just the heart.
All other organs may be also damaged, resulting in strokes, aneurysms, kidney failure, and
blood flow blockage to the extremities. The good news is that preventing heart disease will
also prevent other organ damage by removing atherosclerotic plaques from all arterial vessels.

Figure legend – Diffuse atherosclerosis of the arteries can damage any organ in the body
including the brain (stroke), kidney (renal failure), aorta (aneurysm), and heart (angina and
myocardial infarction). Don’t become a corpse in a medical textbook.
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Chapter A2: A heart attack – why me?
Clinical Vignette
Jed Black is a 55 year old medically retired plumber who had a heart attack 5 years ago. He is
currently taking nine different medications for his heart, his blood pressure, and his diabetes.
He quit smoking ten years ago and has since gained 22 lbs., which he blames on his inability
to exercise. He often gets short of breath when he lies in bed and feels better when he uses
three pillows under his head. He is bitter about the fact that his friends are still working and
apparently healthy. He asks, “Why did I get a heart attack – why me?”
Comment
Atherosclerosis is a progressive disease and does not stop after one heart attack. The reason
that Jed had a heart attack and his friends did not is a result of many factors. Some of the
factors are not under Jed’s control, such as the specific genes he inherited from his parents.
Genes affect many structures and functions in the body such as the size of the heart arteries
and their ability to resist atherosclerosis. However, what Jed has not accepted is that there are
also several factors (called risk factors) that Jed could change to prevent heart attacks. If he
had taken control of these risk factors as a young adult, he would not have suffered a heart
attack at middle age.
Atherosclerotic plaques in Jed’s coronary arteries have been getting larger since birth. The
growth of these plaques is increased by many different risk factors, and their effects add up
over time. Because it is difficult to convince teenagers of their own mortality, the easiest time
to improve one’s lifestyle is during early adulthood. Yearly checkups that include cardiac risk
factor assessment is warranted. Individuals with significant risk factors should have a coronary
artery calcium scan to assess atherosclerosis in their coronary arteries. Any positive score
should be aggressively treated medically and risk factor modification initiated. Heart attacks
are preventable if heart disease is identified early and atherosclerosis reversal therapy is
initiated.
Heart disease risk factors all come together to accelerate the atherosclerotic process. This
involves the movement of LDL cholesterol particles from the blood into the walls of the
coronary arteries (and all other arteries also). Movement of LDL cholesterol is accelerated by
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inflammation throughout the body, which can be increased by obesity, diabetes, smoking, high
LDL cholesterol and many other risk factors. Once inside the artery wall, the LDL particles are
engulfed by macrophages, which merge to form fatty streaks and atherosclerotic plaques.
These plaques eventually rupture into the artery and cause a blockage which prevents blood
from delivering oxygen and nutrients to the heart muscle. This causes pain in the chest, neck,
and arm which is historically called “angina”.
Jed needs to remember that it is not too late to reduce his risk factors. Otherwise, he will likely
have another heart attack that may kill him. Atherosclerosis is a progressive disease and does
not stop with one heart attack. He needs to acknowledge that his previous lifestyle contributed
to his current heart condition and make a serious effort to take charge of his health. A cardiac
rehabilitation program would be a good place for Jed to start. Setting goals of an LDLc of <50
mg/dl and an hsCRP <1.0 mg/L is critical.

Figure legend – A heart attack occurs when LDL cholesterol builds up (as a plaque) in an
artery wall and it ruptures into the lumen. This rupture than causes a blood clot to form over
the rupture that then blocks the artery. Preventing or reversing the LDL cholesterol build up
will prevent a heart attack and result in a long life span.
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Chapter A3: What is Inflammation and is it harmful?
Clinical Vignette
Fred Hersey is a 33 year old male who has severe pains in his hands and feet that his doctor
identified as rheumatoid arthritis. His joints become swollen and warm to the touch. It is
difficult for him to write a letter because of the pain in his hands. His doctor put him on a
medicine which is supposed to reduce the inflammation. He was told that his C-reactive
protein (CRP) was very high and that it was a good measure of inflammation. Although his
LDL cholesterol is “on the low side,” he is worried about heart disease because his father and
one uncle both had a heart attack at an early age. He has heard that inflammation is a major
risk factor for heart disease and wants to know what it is and what he can do about it.
Comment
Inflammation is a term that is used to describe the activity of the body against harmful invaders.
This can take many forms and sometimes we don’t know who the invaders are. However, we
recognize the body’s defenses by the pain, swelling, redness, and warmth that inflammation
causes. Inflammation is caused by the secretion of chemicals from circulating white blood
cells. These chemicals destroy invading bacteria and viruses. The chemicals also attract
more white blood cells (macrophages) which also have the ability to take up cholesterol
particles (LDL cholesterol) and form fatty streaks that eventually turn into atherosclerotic
plaques. These plaques can rupture and cause a heart attack or stroke. Many chronic
diseases such as diabetes, hypertension, arthritis, etc., cause a general (throughout the body)
inflammatory state. In the presence of a chronic inflammatory disease like arthritis, the heart
vessels are vulnerable to damage. This puts the person at risk for heart disease, even though
his/her chronic disease has nothing to do with the heart. Measuring your hsCRP is a good way
to determine if you are at risk because of inflammation. You should try to get your hsCRP
below 1.0 mg/L. Many medicines will reduce inflammation but some have serious side effects.
Relative to preventing heart disease, both statins and ezetimibe reduce inflammation. In
addition, a small dose of aspirin also reduces inflammation. Keep this in mind if your coronary
heart calcium scan is positive.
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Figure legend– Everyone has experienced inflammation. It can occur anywhere in the body,
including the heart. The cause may be an infection, trauma, obesity, genetics, or other
unknown factors. In the heart, it causes LDL cholesterol to form atherosclerotic plaques
(hardening of the arteries). One goal of treatment is to reduce the inflammation. One measure
of inflammation in your body is the blood level of C-reactive protein (hsCRP). A calcium heart
scan will suggest whether inflammation has affected your heart and caused the formation of
dangerous atherosclerotic plaques that have calcified.
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Chapter B1: How do I get started reversing my heart disease?
Clinical Vignette
Sarah and Tony Brown are a married couple in their 40’s. They both have a strong parental
family history of heart attacks and strokes. They have read this book and are convinced that
they do not have to repeat their parents’ fate and die of cardiovascular disease. They realize
that atherosclerosis is a progressive disease which begins at birth and sooner or later, they will
suffer the same fate as their parents unless they make some changes. However, they are
confused about how they should get started since the concept of reversing atherosclerosis is
new to them. Any suggestions?
Comment
It is understandable that Sarah and Tony are a little overwhelmed with their new information.
However, we can assure them that reversing atherosclerosis is not rocket science. It is
actually very easy if they approach it step by step. They have already taken the first step, i.e.,
to acknowledge that no one should die of cardiovascular disease. This acknowledgement will
result in a lifelong commitment to avoid behaviors that put them at risk.
The second step is to review whether they have any of the major risk factors that contribute to
atherosclerosis (hypertension, smoking, diabetes, obesity, and high LDL and/or inflammation).
Getting these risk factors under control is extremely important for lowering the risk (and
progression) of atherosclerosis. This book contains a chapter describing these risk factors and
how to control them.
The third step is for Sarah and Sam to assess their own current status of atherosclerosis in
their heart (and presumably elsewhere, including their brain). This can easily be done with a
coronary artery calcium scan. This inexpensive, noninvasive test will directly measure any
substantial plaque buildup in their heart.

The magnitude of the calcium score will accurately

predict their chance of a cardiovascular event in the future.
The fourth step is to measure their risk as related to their blood lipid profile (especially the LDL
level) and their blood level of inflammation as measured by a high sensitivity C- reactive
protein (hsCRP). Their goal should be an LDL below 50 mg/dl and an hsCRP below 1.0 mg/L.
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It is likely that this goal will require the addition of two inexpensive medications at low dosages:
rosuvastatin 10 mg/day and ezetimibe 10 mg/day.
The fifth step is to change their diet and “Eat Smart.” Eating smart does not mean giving up
anything that they like. It means eating a diet that will not cause weight gain or raise their LDL
level. Chapters throughout the book discuss this approach in more detail. Of course, Sarah
and Sam should discuss these changes with their physician. In our experience, primary care
physicians always support an improved lifestyle and a reduction in atherosclerotic risk.

Figure legend – Many risk factors for heart disease and stroke can be corrected, including
reducing cholesterol in your diet. Some risk factors will require medication from your doctor
and some will necessitate an improvement in your lifestyle. However, having a heart attack or
stroke is much worse than any change you need to make in correcting these risk factors.
Skeptical? Just ask anyone who has had a heart attack or stroke – if they are still alive.
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Chapter B2: Should I monitor heart disease risk factors in my teenage children?
Clinical Vignette
Shirley Blackstone is a 51 year old mother of three healthy teenage boys, ages 12, 15, and 17
years. Their father died last year at age 53 of a heart attack. Their grandfather also had heart
disease and died at age 58 years. Shirley does not want the same fate to befall her children.
Her physician told her that they were probably too young to worry about testing for heart
disease. However, the boys’ pediatrician recommends screening for blood fat disorders.
Shirley wants to know what she should do.
Comment
The answer to Shirley’s dilemma is very important to the long-term health of her children. In
order to make the right decision, she needs to know about the medical condition called familial
hypercholesterolemia. This medical term relates to a gene which carries an inherited form of
high blood cholesterol. Familial hypercholesterolemia is inherited as a gene from one or both
parents. If it is inherited from both parents so that one gene came from each parent, it is called
familial homozygous hypercholesterolemia (a real mouthful). If it comes only from one parent,
it is called familial heterozygous hypercholesterolemia (another big mouthful). Why is this
condition important to Shirley? The reason is that her children may have inherited the gene
from the father or grandfather. What can she do about it?
Familiar hypercholesterolemia is important because it is the number one genetic cause of heart
attacks in the U.S. population. It was discovered by two investigators who received the Nobel
Prize in 1985 for their discovery. In the homozygous form of the disease, children may die of a
heart attack by the age of twenty years if not treated. Thankfully, this form of the disease is
rare. In the general population, the incidence of the heterozygous form is one in 250 people but
it is much more common in people with a family history of heart attacks at an early age (like
Shirley’s). It is easily recognized with a blood test because it is characterized by an increase in
the blood concentration of LDL cholesterol.
The American Academy of Pediatrics recommends that all children be screened for this
condition by the age of 12 years with a blood lipid profile. Treatment should always involve
improved lifestyle including diet and exercise and if necessary, low dose statin therapy.
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The recommendation of early screening is based on the fact that many young people who have
died suddenly in automobile accidents have been shown to already have cholesterol plaques in
their heart’s arteries (premature heart disease). Since atherosclerosis starts in an individual
before birth, is there any reason to wait for adulthood before starting to attack this lethal
disease? The answer to Shirley’s question is for her to have all of her teenage children
screened for familial hypercholesterolemia as soon as possible.

Figure legend - A positive family history of heart disease or stroke is a good indication that
there may be a genetic predisposition to a high blood cholesterol. The best protection against
this deadly disease is early detection, screening, and treatment of all teenage adolescents with
a routine lipid profile blood test. Early treatment will prevent major heart problems later in life.
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Chapter B3: How do I know if my pills are working?
Clinical Vignette
Fred Herman is a 61 year old farmer who has been working on a dairy farm his whole life. His
diet is high in butter, cheese, eggs, and meat. His LDL cholesterol is 145 mg/dl. He smokes
two packs of cigarettes per day and has recently developed type 2 diabetes. He doesn’t like
doctors or the medicines that they prescribe for his hypertension. They make him feel lightheaded. However, he does follow their advice, so he had a calcium heart scan two weeks ago
and his score was 1,230. His doctor immediately put him on triple therapy (rosuvastatin 10
mg/day, ezetimibe 10 mg/day, aspirin 81 mg/day) because of his high heart attack risk. He
asks his doctor “How do I know these pills are working?”
Comment
Fred asks a question that most people ask who take triple therapy because the medications
cause no changes in his body that he can feel. Studies that have actually monitored the
reversal of atherosclerotic plaques in the coronary heart arteries have used sound waves (i.e.,
ultrasound) to visualize the changes in plaque volume with medication. What they have found
is that when the LDL cholesterol goes below 65 mg/dl, that some plaque regression can be
seen. However, the volunteers in these studies usually do not have all the risk factors for heart
disease that Fred has. To account for the added danger of Fred’s risk factors, we recommend
that Fred reduce his LDL cholesterol to below 50 mg/dl. If he does, Fred can be 99% sure that
he is reversing his atherosclerotic plaques.
Although not studied in the same way as LDL cholesterol, inflammation induced by major risk
factors has been shown to be a critical factor in the rupture of atherosclerotic heart plaques.
The stability of the plaque is dependent on the amount of inflammation around the edges of the
plaque’s cap. Therefore, Fred should also monitor the amount of inflammation in his body by
reducing his C-reactive protein (CRP) to less than 1.0 mg/L. His triple therapy will help him do
this as well as getting his diabetes under control and attaining normal body weight. It is also
very important that Fred stop smoking to reduce his inflammation. In other words, controlling
his risk factors and taking his medication is Fred’s best chance to avoid a heart attack. He
should monitor his LDL cholesterol and C-reactive protein every three months for the first year,
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then every six months as long as he is close to the target goal described above. If he does,
Fred can be assured that he reversing his plaques and saving his heart.

.
Figure legend – The best way to tell if your rosuvastatin and ezetimibe pills are working is to
obtain a lipid profile. Compare your LDL cholesterol value with the value you had before
starting the pills. You should wait at least two months after starting your pills before getting
another lipid profile because it takes that long for the pills to reach maximum effectiveness.
Remember that the diet also affects the LDL cholesterol level so be sure to follow the dietary
recommendations in this book.
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Chapter C1: What is a coronary artery calcium scan?
Clinical Vignette
John Whitcome is a 46 year old male with a family history concerning for atherosclerotic heart
disease. His 49 year old brother was recently admitted to the hospital for acute, severe chest
pain and his father died suddenly at the age of 51of an unknown cause. He has mild
hypertension and borderline high cholesterol. He was recently laid off at his work place and
lost his health insurance. His wife is currently working so he is just able to pay his bills. He
wants to know if he has heart disease and his doctor recommends a coronary artery calcium
scan. He wants to know what that test is.
Comment
The coronary artery calcium scan is arguably the best, cost-effective, noninvasive heart test
that has become popular in the last decade. It is based on the observation that the body walls
off foreign bodies with calcium when it can’t readily remove them. When tuberculosis was very
common in the US population, it was often recognized on chest x-rays by the small calcium
deposits in the lungs. The body takes a similar approach to atherosclerotic plaques in your
coronary arteries and deposits calcium in and around the plaque. This can be seen on a chest
CT scan, which takes picture slices through the heart. The test takes about ten minutes and is
noninvasive and painless. The small amount of radiation that you receive is equal to living in
Denver for 3 months. Think of it as a virtual biopsy of the health of your heart.

Besides being noninvasive, the coronary artery calcium scan has several advantages over
other screening tests for heart disease:
1) It’s relatively inexpensive ($50 to $200) in most U.S. cities. Some medical insurance
policies cover at least part of the cost. Check with your insurance carrier.
2) It’s very specific for heart disease – if your score is above zero, heart disease is present.
3) If the score is zero, the chance of having a heart attack in the next ten years is very, very
small.
4) The higher the score, the greater the risk for heart disease.
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In summary, this is a great test for anyone who wants to know what their risk is of having a
future heart attack. This test will also suggest the urgency of medical treatment. If you are an
adult, then you are never too young or too old to have this test, especially if you have any
major risk factors for heart disease (diabetes, hypertension, obesity, smoking, and/or elevated
blood LDL cholesterol). It will encourage you to improve your lifestyle and reduce your risk of
heart disease. We highly recommend it.

Figure legend - This figure of a coronary artery calcium scan demonstrates calcium deposits
in a heart vessel (normally white but colored red in this figure for emphasis). Parts of the ribs
in the chest wall are also seen. The person with this scan would have an elevated coronary
artery calcium score. However, only the calcium in the four main coronary arteries is counted
when calculating the total score. Pictures of multiple slices of the heart and blood vessels are
taken between heart beats. This is one slice.
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Chapter C2: Why should I have a calcium heart scan?
Clinical Vignette
Michael Neff, a 45 year old male, is a professor at a university. He complains of tightening in
his chest when sitting at home in the evening preparing for the next day’s lectures. He admits
that he gets nervous when preparing and giving lectures to very large classes. He gets no
chest pain at any other time. His father had a heart attack at age 51. His wife is worried that
he is about to have a heart attack and asks him to see a doctor. His cholesterol is in the
average range and he has no other risk factors for a heart attack except for mild obesity and
his father’s history. He decides to have a calcium heart scan which shows no calcium in any
heart blood vessels. He is greatly relieved with this test result since the incidence of a heart
attack is very low in people with a coronary artery calcium score of zero. However, to be on
the safe side, he decides to increase his exercise program, eat healthier foods, and to lose ten
pounds. He agrees to repeat the calcium heart scan in five years.
Comment
A calcium heart scan can be very reassuring to people worried about their heart, and may
motivate their changing to a healthier lifestyle. If calcium is present in the heart arteries, it
always means that these vessels have a dangerous buildup of cholesterol plaque. These
plaques can rupture, resulting in a blood clot in the heart arteries, causing a heart attack. This
is the reason that a calcium heart scan with a positive score should immediately be treated (as
discussed in other chapters). However, when the scan shows no calcium, then immediate
medical treatment is not necessary. Because plaque buildup can occur as people get older
and calcification of these plaques will eventually occur, a repeat calcium heart scan is a good
way to monitor your risk for a future heart attack. We recommend a repeat calcium heart scan
at least every five years as a good preventative test. Other preventative tests are done on a
periodic basis (such as a colonoscopy or mammogram), so why not also check for heart
disease? Since heart disease is reversible when identified early, this test can save your life.
Compared to other diagnostic tests, a calcium heart scan is very inexpensive and noninvasive.
It takes about 10 minutes to complete and the only preparation by the patient that is needed is
to avoid coffee the morning of the test (caffeine increases your heart rate, which makes it
difficult for the CAT scan to take pictures of your heart between heart beats). We have
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included a copy of the brochure in the Appendix that we give our patients before their coronary
heart scan. We think that you will agree that this is the most pleasant diagnostic test that you
have ever taken.

Figure legend – A coronary calcium heart scan is a noninvasive test that requires10 minutes
and takes multiple pictures of your heart arteries. The amount of calcium in your heart arteries
predicts your chance of a heart attack in the future. It is similar to throwing a life preserver to a
drowning person. It is the best way to tell you about your heart and whether or not it needs
help.
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Chapter C3: Where can I get a calcium heart scan?
Clinical Vignette
Rebecca Vigil is a 51 year old postal worker who has three major risk factors for atherosclerotic
heart disease. She lives in a small, rural town outside of Kansas City, Missouri. She read a
magazine article on the benefits of a calcium heart scan and decides both she and her
husband should obtain one. Her local physician is not familiar with this test and does not know
where she can have one done. How should she solve this dilemma?
Comment
Rebecca asks a good question – actually three good questions: 1) Where can I get a calcium
heart scan? 2) How much will it cost?, and 3) Do I need a doctor’s prescription? Let’s answer
each question in turn. To our knowledge, there is no country-wide database that lists all of the
locations doing calcium heart scans in the U.S. However, all institutions that do CT (computed
tomography) scans are technically able to do calcium heart scans because they already have
the necessary equipment. However, they do need to have a trained technician and an
administrative setup to handle the paperwork. The easiest approach to finding a facility near
your location is to go to the internet and then to the website of the nearest hospital or
radiological group in your town. At their website, go to their radiology department and see if
calcium heart scans are listed as procedures that they offer. If nothing is listed, call their
radiology department and ask specifically whether they perform coronary artery calcium heart
scans? Alternatively, you can go to your telephone book’s yellow pages and look up the
number of a radiology facility near you and call them to ask the same questions. With a little
perseverance, you will find a facility doing calcium heart scans.
The second question you should ask is the cost of the calcium heart scan. The cost should
range between $50 and $200. Don’t ask us why there is a fourfold difference in cost – it’s
known as a profit margin. If it exceeds this cost, we suggest finding another location for your
scan. In addition, some insurance companies will reimburse you for the cost of the scan. You
will need to check with your insurance company because reimbursement varies from state to
state. For example, in some parts of the southwest U.S., Medicare will reimburse you $94
toward the cost of the scan.
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The third question is whether you need a doctor’s prescription or order to obtain a calcium
heart scan. This is variable – some facilities do require an order from your doctor and some do
not. You need to ask the facility that you are planning to go to for your scan. We strongly
recommend that whether you get a doctor’s order or not, that you have a physician to discuss
the results with you before having the scan. Getting a calcium heart scan will do nothing
toward saving your life if you don’t get appropriate medical treatment if the scan is positive.

Figure legend – A calcium heart scan takes about ten minutes. It’s a simple test requiring no
injections, no pills, no intravenous fluid lines, and very little preparation. All facilities with a CT
scanner can do this test but may not be administratively set up to process the data and billings.
All cities and most large towns will have facilities to do a calcium scan. Contact your local
radiological CT facilities or hospital and inquire about calcium heart scanning.
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Chapter D1: What kind of Doctor should advise me about my heart?
Clinical Vignette
Robert Gatsby is a 51 year old accountant for a local publishing firm. He asked “Who should I
see about my heart?” He wants advice about keeping his heart healthy because one of his
close friends just died of a heart attack. This scared him because his friend was younger than
he and had no symptoms of chest pain or other warning signs before collapsing while walking
his dog.
Comment
This is a very common question. Many people believe that the answer to Robert’s question
would be a cardiologist because this medical specialty deals directly with heart disease. The
problem with arranging a consultation with a cardiologist is that it is often very difficult to
schedule an appointment, and cardiologists usually treat already established heart disease or
signs and symptoms of serious heart disease. Alternatively, your primary care giver is very
competent to identify if you have heart disease. He/she will perform a history and physical
exam including listening to your heart and ordering the appropriate laboratory and radiographic
tests. It is very important that you make a list of the testing you should obtain to be certain that
your primary care giver does not omit important information.
The first goal is to identify any risk factors for heart disease that you might have. Smoking,
obesity, and high blood pressure will be identified by history and physical. Laboratory blood
tests will identify diabetes (by hemoglobin A1C), abnormal blood fats (by a lipid profile for high
LDL cholesterol), and high inflammation (by a high sensitivity CRP). An electrocardiogram will
demonstrate if the electrical conduction through your heart is normal. Most importantly, a
coronary artery calcium scan will tell you directly if any calcified plaques are present in your
heart vessels. You should discuss the results of each of these tests with your primary care
giver before deciding on therapy. If all of the above tests are normal (or negative), we
recommend repeating them at least at five year intervals.
Much more likely, however, is that some of the tests will be abnormal. Your primary care giver
can give you guidance and suggestions for improvement.
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Of all the above tests, the coronary artery calcium score is the most important relative to the
health of your heart. In summary, it represents all of the potential insults that may have
occurred in the past that would damage your heart. If the scan is positive, then you definitely
need preventive therapy. Several chapters in this book discuss our recommendations for this
therapy, particularly improvement in lifestyle and reduction of LDL cholesterol to less than 50
mg/dl. To return to Robert’s question of what type of physician he should see for his heart, we
recommend his primary care giver, with the caveat that Robert should bring a list of tests (listed
above) with him to his caregiver’s visit so that all of the necessary information about his heart
will be obtained.

Figure legend – Robert needs to consult with his primary care giver to find out about the
health of his heart. All the tests that he needs are noninvasive and will tell him what his next
step should be. We recommend taking a copy of this book chapter to his medical visit to be
certain that all the necessary tests will be done.
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Chapter D2: Do I need a stress test?
Clinical Vignette
George Akins is a 44 year old surveyor with a positive family history of heart disease (in his
father and brother). Recently, while out surveying a property, he became short of breath. He
attributed this episode to his being overweight and smoking for 20 years (he recently quit). His
electrocardiogram (heart tracing) was normal but his physician recommended a cardiac stress
test. George’s medical insurance covers only 50% of the $545 that the test costs. George
asks, “What is a stress test and what will it tell me about my heart?”
Comment
George is smart to ask this question. The answer may surprise him. A stress test is a
commonly ordered test to assess a person’s heart function if limited blood flow to the heart is
suspected. There are several ways to perform this test, but in its simplest form the patient is
first connected to an electrocardiogram with wire leads attached to different parts of the chest.
The individual then walks on a raised treadmill to increase his/her heart rate. When the heart
rate reaches a maximum rate, the technician examines the electrocardiogram tracing to see if
there are any changes in electrical activity to suggest limited blood flow to the heart (this is
called “ischemia”). This test is usually safe, although fatalities from heart attacks during the
procedure have occurred.
The main problem with this test is that the result can be normal when the patient actually has
progressing heart disease due to reduced blood flow to the heart. If this reduced blood supply
is less than 50% of normal, then exercise will not cause a positive stress test, thus failing to
recognize significant heart disease. This is a dangerous situation because the physician will
not treat the patient aggressively for heart disease. Even when the test is positive and
suggestive of serious heart disease, it gives no indication as to where the coronary vessel
obstruction might be located. According to the US Preventive Services Task Force, “The
primary tangible harm of screening exercise tolerance testing is the potential for medical
complications related to cardiac catheterization done to further evaluate a positive result.”
They do not recommend this test be done in individuals without chest pain at rest (called
unstable angina).

38

A better approach for George to learn about the condition of his heart is to have his physician
order a coronary artery calcium heart scan. This test costs only $150 or less, takes 10
minutes, and is noninvasive. Based on the resulting score of this test, George can accurately
predict his chances of having a cardiovascular event for the next ten or more years. The result
will also tell his physician how aggressively to treat him. If his score is zero, then George has a
predictable, excellent ten year survival prognosis. However, George should repeat the calcium
heart scan in five years in case the score increases above zero and aggressive medical
treatment is needed.

Figure legend – As the name implies, a cardiac stress test stresses the heart muscle and
changes its electrical activity. This occurs when sufficient blood supply to the heart becomes
limited by atherosclerotic plaques. There are several disadvantages to performing this test, the
primary one is its poor sensitivity to detect underlying atherosclerotic heart disease. We rarely
recommend this test.

39

Chapter D3: Why Should I have another calcium heart scan in 5 years?
Clinical Vignette
Five years ago Jack Griego, a 42 year old carpenter, was worried about his heart because his
father had a heart attack at age 55 years. Jack felt fine and had no other risk factors for heart
disease. His laboratory studies at that time were normal. His doctor suggested that he get a
calcium heart scan to check on his heart status. He did as his doctor suggested and was
greatly relieved that his calcium heart scan score was zero. His doctor suggested that he get a
repeat scan in five years. Five years later Jack underwent a repeat calcium heart scan.
During the past five years he has gained 23 pounds and developed both diabetes and
hypertension. His repeat heart scan now has a score of 233. His doctor immediately
encouraged him to lose weight, start to exercise, and take medication to lower his cholesterol
level. If he follows his doctor’s advice, his repeat heart scan probably saved his life.
Comment
A calcium heart scan should be considered an evaluation of the current status of your heart. It
reflects all the previous years of your life and the risks to which your heart was exposed. It
does not exclude mild heart disease since calcium collects in your heart vessels after the heart
has developed atherosclerotic plaques containing no calcium. When the scan turns positive,
you know that you definitely have plaques in your heart’s blood vessels which can rupture at
any minute. Risk factors such as hypertension, diabetes, smoking, and high LDL cholesterol
definitely increase your chances of making plaques in your heart arteries.

A repeat heart

scan every five years will keep you informed of your heart’s status. The higher the score, the
more chance you have of dying of a heart attack. It is a great wake up call to get energized to
improve your lifestyle and lower your risk factors. Many studies have proven that heart disease
is reversible if you identify it early and reduce your risk factors.
Why five years? You should think of a coronary artery calcium heart scan as a preventive
measure to catch heart disease early, before serious damage has been done. This approach
is accepted for the prevention of other diseases, such as colon cancer (colonoscopy), cervical
cancer (PAP smear), and breast cancer (mammography). Once the calcium score turns
positive, the chance of a future heart attack greatly increases, so aggressive medical therapy is
warranted. If you have significant risk factors for heart disease (diabetes, hypertension,
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obesity, smoking, or high LDL cholesterol levels) then a rescan in less than 5 years is
recommended. People who take preventive testing seriously enjoy longer happier lives.

Figure legend – A calcium heart scan takes 10 minutes and is painless and noninvasive. It is
the best test to see if you have atherosclerotic heart disease. As with any screening test, the
score can become elevated as you get older. Therefore, if your score is zero, repeat it in 5
years. It may save your life!
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Chapter E1: How do I reverse my heart disease?
Clinical Vignette
Harold Caruthers is a 66 year old retired plumber. He is enjoying retired life by visiting his
grandchildren and rooting for his favorite football team. His risk factors for heart disease
include prediabetes, mild hypertension, and a younger brother who recently had a heart attack.
His physician recommended that he get a coronary calcium heart scan to check on the status
of his heart. Much to his dismay, his calcium score was returned at 660, and most of the
calcium was located in the anterior descending coronary artery (dangerous location). He
wants to know how he can reverse this slowly progressive development of heart disease
plaque.
Comment
The good news is that plaques in the coronary heart vessels are reversible. The bad news is
that it takes a finite time to do this and requires a change in lifestyle habits and medication.
Harold needs to remember that his heart disease has been developing since he was born and
therefore he should not expect instant reversal. Medical studies have shown that coronary
heart plaques start to become stabilized within 30 days of starting aggressive medical therapy
and lifestyle changes. Furthermore, heart disease reversal can be shown to start to occur
within one year, with more reversal at two years. Presumably, this reversal of heart disease
continues for as long as the individual maintains a favorable lifestyle and aggressive medical
therapy.
Another chapter details the lifestyle changes that are necessary to reverse atherosclerosis but
briefly it entails “eating smart.” This term means reducing the amount of cholesterol, saturated
fat, and trans fats in your diet. It means reading the labels on the foods that you buy at the
store. It also means taking medication to reduce your LDL cholesterol level below 50 mg/dl.
Your success at reversing your atherosclerosis is easy to monitor. If your LDL cholesterol is
significantly above 50 mg/dl and you have poorly controlled cardiovascular risk factors, your
heart disease is progressing. If your LDL is below 50 mg/dl and all risk factors are controlled,
you are reversing your atherosclerosis.
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As detailed in the chapter on inflammation, reducing the blood marker for inflammation
(hsCRP) is also very important, since inflammation is necessary for atherosclerotic plaque
buildup. Your goal should be an hsCRP level below 1.0 mg/L. Inflammation is reduced by
medication (rosuvastatin, ezetimibe, and aspirin) and a reduction in cardiovascular risk factors.
All of these factors are described in detail in other chapters in this book.

Figure legend – At any given time, cholesterol (primarily LDL cholesterol) is both accumulating
in the walls of your arteries and being simultaneously removed by LDL cholesterol receptors on
your liver. Reversal of atherosclerosis requires that removal exceed buildup. This is best
accomplished by reducing your level of LDL cholesterol level via improved lifestyle and
medication.
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Chapter E2: How long will it take to reverse my heart disease?
Clinical Vignette
Dan Brownlee is a 49 year old bus driver who quit smoking cigarettes 2 years ago. He blames
his obesity on his sedentary job and his hypertension to the stress of dealing with the public.
His diabetes is not well-controlled. On the advice of his physician he had a coronary artery
calcium scan. His physician told him that his score was 1,135, which put him at major risk for a
heart attack within the next ten years. This high score caused him much concern and he
assured his physician that he would improve his lifestyle and take his blood pressure
medications. He knows that he needs to reduce his LDL cholesterol level to less than 50 mg/dl
with appropriate medications and his hsCRP to less than 1 mg/L. If he follows his physician’s
advice, he wants to know “How long will it take me to reverse the plaques in my heart?”
Comment
Dan must first understand that his heart disease has been developing since he was an infant.
It has been accelerated by his less than ideal lifestyle and his poor compliance with taking
prescribed medications. The rate of reversal of his heart disease will depend to a great extent
on his willingness to comply with his doctor’s recommendations. Assuming that he is compliant
and gets his diabetes, hypertension, and obesity under control, his outlook is good.
The first goal of therapy is to stabilize the plaques in his arteries. Stabilization includes
reducing the inflammation in the plaque, thickening the plaque’s cap, and reducing the amount
of LDL cholesterol in the plaque itself. Studies have demonstrated that plaques can be
stabilized within 30 days of starting a statin. Furthermore, reversal of some plaques can be
demonstrated after 12 months and at two years, more reversal can be demonstrated.

The

rate of reversal depends on many factors, but control of atherosclerotic risk factors is
paramount. Since atherosclerotic plaques can erupt into the coronary artery lumen at any
time, Dan should not delay in initiating his lifestyle and medication changes.
Complete removal of the atherosclerotic plaque is not necessary to prevent a heart attack. In
fact, the calcium in Dan’s plaques will probably remain in place for the rest of his life. It will do
him no harm. But it is the reason that we do not usually recommend repeating the coronary
artery calcium score once the individual has a high value. It will always be high.
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Figure legend – Atherosclerosis starts in childhood and continues throughout life. However,
this process can be reversed by controlling cardiovascular risk factors and reducing LDL
cholesterol. The reversal process begins within one month of initiating changes in risk factors
and is easily demonstrable within one year. Within two years, many studies have shown
dramatic reversal with a concomitant decrease in the number of heart attacks.
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Chapter E3: What therapy do national organizations recommend to save my heart?
Clinical Vignette
Stanley Parks is a 44 year old primary care physician who has a busy practice in a small
Colorado town. He tries to keep up-to-date with medical advances by relying on treatment
guidelines published by national organizations. He recently read that the American Heart
Association does not recommend specific LDL cholesterol nor hsCRP goals. Instead, they
recommend placing the individual at risk of a heart attack on statins. The greater the risk, the
more potent the statin. The amount of risk is determined by the number and severity of
specific risk factors. Stanley would like to know why we recommend a different approach.
Comment
Stanley’s question is frequently asked by many healthcare practitioners. There are several
parts to the answer. First, there are at least 21 national and international organizations that
have published guidelines on the prevention of heart disease. A recent review of all of these
guidelines comes to one major conclusion, i.e., that none of the guidelines agrees with the
other. This may seem strange because all the members of the guideline committees have
access to the same medical information. However, each guideline committee is composed of
different experts who have their own beliefs and biases on how to prevent heart disease.
Thus, a physician can choose to follow any guideline he/she wants and still deliver the medical
standard of care. No wonder Stanley is confused.
Second, many physicians have criticized the American Heart Association guidelines as being
blinded to the fact that every study that has examined the benefits of lowering LDL cholesterol
has concluded that the lower the LDLc achieved, the fewer heart attacks have occurred. In
other words, “the lower, the better.” This conclusion is true even when the LDL cholesterol
level starts at 70 mg/dl and is reduced significantly below that number. This is one reason we
recommend an LDL cholesterol target of <50 mg/dl, a concentration present when you were
born and that is absolutely safe.
Third, having specific goals for both LDL cholesterol and hsCRP increases patient compliance
because he/she knows the target and why the physician is recommending therapy. Studies
have shown that 50% of patients no longer take their statins at the end of two years for various
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reasons, including lack of a specific goal. It is important that patients know that they are
reducing their cardiovascular risk when they are taking statin medication. They can do this by
monitoring their LDL cholesterol level.
Fourth, there is a huge amount of medical literature on the prevention and treatment of heart
disease. It takes many hours of reading and study to keep abreast of this literature. Many socalled experts do not have the time to stay up-to-date on the latest advances on the cause of
heart disease and its optimal treatment. Thus, recommendations from various organizations
are bound to be different.

Figure legend – There are 21 national and international organizations that publish treatment
recommendations for individuals at elevated risk for heart disease. Not surprisingly, their
recommendations are not in good agreement with each other since the experts on the
recommendation panels are all different with various backgrounds and levels of expertise. Our
recommendations are based on what causes a heart attack and what has been shown to
prevent and reverse heart disease.
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Chapter F1: What if I already had a heart attack?
Clinical Vignette
Jack French is a 55 year old male business man employed by a local stationery store chain.
He had a heart attack three years ago, followed by triple bypass surgery. He has been doing
reasonably well since his heart attack, but occasionally gets chest pain and shortness of breath
when he walks uphill. He is worried that his bypass heart arteries are becoming clogged with
cholesterol like they did before he had a heart attack. His cardiologist has him on 80 mg/day of
Lipitor (atorvastatin). His LDL cholesterol is 92 mg/dl and his hsCRP is 3.5 mg/L
(unfortunately, neither substance is at goal). He asks if there is anything else he should do to
prevent another heart attack.
Comment
Jack is wise to be concerned about the arteries in his heart. It is common for people who have
had a heart attack followed by a surgical procedure (either a stent or a quadruple cardiac
bypass) to think that they are cured from atherosclerosis. Nothing could be further from the
truth. It turns out that the veins or arteries that are used to bypass clogged heart arteries also
become clogged at a higher rate than his original heart arteries. Jack will have many diseased
heart arteries that were not bypassed that have the ability to become obstructive and to cause
a second heart attack.
The good news is that Jack can do much to reduce his risk for a second heart attack. He
should follow the same recommendations as individuals with a high coronary artery calcium
score. He needs to reverse all of the atherosclerosis in both his heart and his bypassed
arteries. This includes reducing any risk factors for heart disease (smoking, hypertension, and
diabetes), increasing his exercise program, and avoiding foods high in cholesterol and
saturated fat. We would also recommend that he speak to his doctor about changing his
Lipitor regimen to 10 mg/day of rosuvastatin and 10 mg/day of ezetimibe. This regimen is
more effective than 80 mg of atorvastatin in reducing his LDL cholesterol with fewer side
effects. Those two medications will also reduce the inflammation in his arteries. Jack’s goal
should be an LDLc below 50 mg/dl and a hsCRP below 1.0 mg/L. Adding a baby aspirin (81
mg/day) to his regimen will further reduce his hsCRP by about 20%.
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There is no reason for Jack to get a coronary artery calcium score. He already knows that he
has serious heart disease. He is lucky to have survived a heart attack and open heart surgery.
It is always better to prevent heart disease than to try to reverse it after a heart attack. Some
parts of Jack’s heart muscle will never work again.

Figure legend – A person who already has had a heart attack (and survived) will have some
dead heart muscle in his heart. For this reason, his heart will not pump blood as efficiently as a
normal heart. This may result in the inability to climb stairs, walk without oxygen, or require
several medications to maintain the heart in a functional condition. Once an individual has had
a heart attack, he/she is at a very high risk for another heart attack. Every effort should be
made toward controlling heart attack risk factors. Reducing his LDLc below 50 mg/dl and his
hsCRP below 1.0 mg/L should be his two goals to avoid future heart attacks.
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Chapter F2: How much will preventing a heart attack cost?
Clinical Vignette
Jeff Small is a 33 year old tennis and golf instructor at a local country club. He stays in good
physical shape and works out regularly at the gym. Unfortunately, he was born with a genetic
predisposition to atherosclerosis, having elevated levels of LDL cholesterol. His father had a
heart attack at the age of 41 years and his grandfather also died of a heart attack at a young
age. He has some health insurance but his copay is substantial. He realizes that preventative
treatment will be lifelong and he reasonably asks “How much will prevention cost me?”
Comment
We are pleased that Jeff asked this question. Consideration of cost should always be included
in a treatment plan. In any cost analysis, certain assumptions need to be made. First, the cost
will be different for different individuals based on their medical policy and the copay for which
they have signed up. We will assume that Jeff’s copay is 20% for hospitalization costs.
Second, costs change (usually increase) for medical procedures so we will use 2018 estimated
costs. Third, the more medical procedures that are done and the longer the hospitalization, the
higher the costs.
Based on the above assumptions, it is possible to estimate both the cost of prevention and the
cost of an atherosclerotic event (such as a heart attack). First, what does it cost to prevent a
heart attack? The cost of lifestyle changes and “eating smart” is zero. These health changes
should be done irrespective of preventing heart disease. The only other cost is the prescribed
medications. The maximum cost of all three preventive medications added together will not
exceed one dollar/day. Many insurance plans actually provide these medications at no cost to
the policy holder. If we assume that Jeff will live to the age of 80 years, then his maximum
lifetime cost for medications will be $17,155 (47 years X $1.00/day X 365 days = $17,155).
This payment will be spread over 47 years at $365/year.
The second consideration is what Jeff’s expenses will be if he has a cardiovascular event (for
example, acute chest pain or heart attack). An emergency room visit and subsequent
hospitalization can easily be $10,000. A coronary angiogram (to identify the location of the
obstruction) costs at least $5,000. A stent (a wire mesh to open the arterial blockage) costs at
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least $30,000. This best scenario for Jeff will easily cost $45,000. Since Jeff’s co-pay is 20%,
he would incur a bill for $9,000 in one year! A less favorable outcome for Jeff would be a major
heart attack ($100,000 with a co-pay of $20,000) followed by a surgical coronary bypass
procedure ($500,000 with a co-pay of $100,000). Jeff will also be placed on several much
more expensive medications (with many serious side effects) for the rest of his shortened
lifespan. It is also likely that Jeff will have additional heart attacks and several hospitalizations
for heart failure.
From the above summary, it should be clear that prevention of a heart attack is much less
expensive than ignoring the cardiac risk factors and developing a deadly cardiovascular event.
And the pain and suffering of a heart attack for Jeff and his family have not even been
considered!

Figure legend – Bills versus pills - Prevention of atherosclerosis is much cheaper than treating
a heart attack. If you want to save money, obtain a calcium heart scan and if positive, take
ezetimibe plus rosuvastatin at $1 per day, full price. Most medical insurance companies now
provide these medications either at no co-pay or minimum co-pay.
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Chapter F3: How much will I benefit from triple therapy?
Clinical Vignette
Suzanne Block is a 55 year old waitress with a positive family history of heart attacks in her
mother and grandmother. Her coronary artery scan score is 809 and she is very concerned for
her future health. She has no other cardiac risk factors except for an LDL cholesterol of 157
and an elevated inflammation marker (hsCRP) of 3.3 mg/L. Her physician has recommended
a maximum dose of a statin. However, she has read this book and believes that triple therapy
might be better. Suzanne would like to know what results she can expect from triple therapy
(once daily rosuvastatin 10 mg, ezetimibe 10 mg, and a low dose of aspirin of 81 mg).
Comment
As you might expect, people respond differently to medications. However, almost all
individuals in our clinic reduce their LDL cholesterol below 50 mg/dl on triple therapy as long as
they follow a prudent diet. The reason that various people respond differently are multiple:
First, the higher the starting LDL cholesterol value, the greater will be the percent response to
triple therapy. This is good news for Suzanne because her baseline LDL cholesterol is
significantly elevated.
Second, statins (e.g., rosuvastatin) work by suppressing the liver’s production of cholesterol.
People have different liver sensitivity to statins so that the greater the sensitivity, the greater
the suppression. The reason for this variability is not known. What is known is that the
greatest percent suppression is at the lowest statin dose (75% effectiveness). Therefore, we
always start therapy with a low statin dose of rosuvastatin (10 mg/day).
Third, different people normally absorb cholesterol from their gut at variable amounts.
Therefore, ezetimibe, which blocks 50% of cholesterol absorption, will have a greater effect at
lowering LDL cholesterol in people with a normally greater percent absorption of cholesterol.
Fourth, the benefits of triple therapy depend on the food intake of saturated fats. Avoidance of
saturated fats and cholesterol will greatly improve the response to triple therapy. “Eating
Smart” should be part of the lifestyle change that individuals at risk for heart disease should
take seriously.
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The good news is that all three components of triple therapy will reduce inflammation, so
Suzanne can expect her hsCRP to be significantly reduced (approximately 30%). Aspirin itself
will reduce it 20%. Most importantly, good compliance with the medications and lifestyle
change is paramount to obtaining a great response to triple therapy. We suggest that you use
a pill box and take your medications at the same time every day.

Figure legend – Triple therapy should reduce your LDL cholesterol to the healthy level at birth
(50 mg/dl). We have found that our patients are both pleased and amazed at their response to
this approach to preventing heart disease. Remember to wait at least six weeks to remeasure
your LDL cholesterol response because the changes that occur require this amount of time to
see a maximal response.
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Winter in The Gila National Forest near Silver City, New Mexico. The
Continentel Divide Trail runs from left to right through these mountains.
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Chapter G1: What is my Lipid profile?
Clinical Vignette
Nancy Kraul is a 44 year old lady who visits her doctor once a year for an annual checkup.
She believes that preventing disease is much better than trying to treat it after it has occurred
(a very good plan). She always gets a set of blood tests before her visits so that her doctor
can make certain that all of her organ systems are in good order. At her last visit, her doctor
told her that her cholesterol level was too high and she needed to improve her lifestyle (lose
weight and exercise more) to get the level down. She is worried because her older sister had a
heart attack last year. She wants to know more about what a high cholesterol really means.
Comment
Your doctor never really orders just a cholesterol level. What he/she does order is a lipid
profile. This test is a grouping of four different blood tests, all of which measure a different fat
that circulates in your blood. The first component of a lipid profile is the total cholesterol. It
represents the total amount of cholesterol in all the fat particles in your blood. The second
component is the HDL cholesterol. The HD stands for “high density” which comes from the
fact that it is very dense (i.e., heavy) when spun in a centrifuge. It carries the cholesterol that is
traveling from your heart arteries back to your liver for disposal. It is often called the “good
cholesterol” because it is reducing atherosclerosis. The third component of the lipid profile is
the triglyceride level. This is the fat that your body burns for energy. It is an important indicator
of problems with energy metabolism, often seen in diabetes and obesity. The final component
in the lipid profile is the LDL cholesterol. The LD stands for “low density” which comes from the
observation that it is less dense (lighter) than HDL cholesterol when spun in a centrifuge. It is
often called the “bad cholesterol” because it is the cholesterol that gets deposited into your
arteries.
The total cholesterol level is not a very useful number because it contains both the good
cholesterol (HDL cholesterol) and the bad cholesterol (LDL cholesterol). The total cholesterol
can be high because you have lots of good cholesterol (HDL cholesterol) or lots of bad
cholesterol (LDL cholesterol). Obviously, you would want to have a lot of the former and very
little of the latter, but the total cholesterol does not tell you about either component. Therefore,
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it’s best to focus your attention on the other components of the Lipid profile. We have more to
say about these components in other chapters.

Figure legend - The components of the lipid profile. As shown above, the total cholesterol
contains all of the cholesterol that is present in the other components of the lipid profile. The
HDL cholesterol is the heaviest component, the triglycerides are the lightest. The LDL is
midway between these two in weight. Each of these components has a different function in
your body. You should compare your values with the values shown in the above chart. Are
you at risk?
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Chapter G2: What should I tell my doctor?
Clinical Vignette
Greg Fineman is a 44 year old mechanic who is worried about a heart attack because until
recently he had most of the major risk factors for heart disease. Six months ago he had a
coronary artery calcium score of 1,530. This encouraged him to lose weight, quit smoking, and
take his diabetes and high blood pressure medications. His physician was not worried about
his LDL cholesterol since it was normal at 90 mg/dl. However, Greg now understands that he
needs to reduce his LDL down to 50 mg/dl and his CRP below 1.0 mg/L if he wants be sure of
reversing his proven heart disease. Greg asks “Won’t my physician be upset if I ask him to
order an hsCRP (for inflammation assessment) and prescribe rosuvastatin and ezetimibe to
lower my LDL?
Comment
Greg’s concern about his physician being upset is a very common misconception that many
patients have about requesting a new treatment. The primary goal for 99% of physicians is to
find the best treatment for their patients. Physicians also realize that medical therapy is rapidly
changing and just keeping up to date is a major challenge. In fact, studies have demonstrated
that on average, it takes 17 years for major medical advances to actually reach the patient.
This long duration may surprise you but there are several reasons that it takes so long.
First, medical therapy for every disease is rapidly changing such that every year new
medicines and techniques become available. Since the practicing physician is no longer
attending school, keeping current on various topics is almost impossible. Most physicians try
to keep up to date by reading medical journals and attending medical seminars on new
therapies. This has to be done either after a long day in the office or during vacation time. Not
an easy task. Second, the Food and Drug Administration (FDA) must approve a new treatment
before physicians will prescribe it and health insurance companies will cover it. However, the
FDA usually requires many long and expensive clinical trials to test the medication’s efficacy
and to define its side effects. This requirement can take many years and cost millions of
dollars to obtain the necessary clinical trial data. Third, medical insurance companies need to
decide whether to cover the cost of the new drug or procedure and what the patient’s copay
will be (you are probably familiar with this problem). Fourth, scientific societies (e.g., the
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American Heart Association) need to publish recommendations of how they believe the drug
should be used. Many committees making these recommendations only meet every few years
and their members may have significant conflicts of interest with the new therapy. We have
included a chapter describing this problem.
From the above paragraph, you can understand why your physician may not be familiar with
the latest treatments to prevent heart attacks. However, physicians appreciate learning new
treatments that will help their patients. We suggest you give your physician a copy of the
chapters from this book that address your specific treatment. Each chapter has pertinent
references documenting the scientific basis for its position. You can also tell him/her that he
can contact us for questions by emailing the authors at HSC-endo@salud.unm.edu. Trust us,
he will appreciate your contribution.

Figure legend – Physicians have a very difficult time keeping up to date with the latest
treatments and technology such as the coronary artery calcium heart scan. Patients can help
physicians by providing them with new information and appropriate reading material. Your
physician will appreciate it.
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Chapter G3: Ten golden rules for saving your heart
Clinical Vignette
Armand Hanover is a 55 year old dentist with a wife, three children, and one grandchild. He
enjoys interacting with his family, especially during the holidays. He has read this book and
has made several changes in his lifestyle to reach the recommended health goals. He would
like to know whether the key points that are made in this book can be condensed to ten rules
that he can remember and follow.
Comment
Armand presents a challenge to the authors because each of the 50 chapters makes a
separate clinical point. After much discussion, here are our ten most important points that we
would like Armand to remember.
Rule #1 - Heart disease is preventable and reversible. With appropriate lifestyle and therapy,
no one should have a heart attack or die from atherosclerotic heart disease.
Rule #2 - Fifty percent of people who have a heart attack die before arriving at the hospital.
The other 50% of people will have impaired physical activity depending on the amount of heart
muscle damage they incur.
Rule #3 – Control of correctable cardiac risk factors for heart disease (hypertension, diabetes,
smoking, obesity, and LDL cholesterol) is extremely important for reducing the occurrence and
progression of heart disease.
Rule #4 – Heart disease starts before birth and continues to increase throughout life. This is
why increasing age is a non-correctable risk factor for having a heart attack. This is also why
diagnosis and treatment to prevent heart disease should start early in life.
Rule #5 – Reversal of established heart disease occurs when LDL cholesterol is reduced
below a concentration of approximately 65 mg/dl. The presence of cardiac risk factors will
require a lower number. Our goal of 50 mg/dl provides a safety margin to assure
atherosclerosis reversal.
Rule #6 - Throughout the entire range of LDL cholesterol, the lower the LDL, the less heart
disease occurs.

A diet low in saturated fats is critical for achieving a low LDL.
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Rule #7 – The two main causes of heart disease are LDL cholesterol and inflammation
(measured by C-reactive protein). Both are required to develop atherosclerotic plaques.
Rule #8 – Everyone’s LDL goal should be less than 50 mg/dl, the level you were born with. No
adult needs any circulating LDL to be healthy because all cells can make their own cholesterol.
Rule #9 – Everyone’s inflammation goal should be a C-reactive protein less than 1.0 mg/L.
Low dose coated aspirin (81 mg) /day will reduce inflammation about 20%.
Rule #10 – Rosuvastatin 10 mg/day and ezetimibe 10 mg/day are the two best medications to
lower LDL cholesterol. Side effects at these low dosages are very rare.
We hope we have met Armand’s request for ten rules to remember.

Figure legend – Preventing heart disease is not difficult. However, it will not happen if you
don’t remember a few important rules. Changing your lifestyle to reduce your risk factors and
taking medication to reduce your LDL cholesterol and inflammation are critical ingredients for
preventing and reversing heart disease.
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Chapter H1: Why should I worry about cardiac risk factors?
Clinical Vignette
Toby Jones is a 55 year old used car salesman who reluctantly went for a medical checkup at
the insistence of his employer. Toby has been overweight his whole life, smokes one pack of
cigarettes per day, has type 2 diabetes, and was told that his cholesterol was too high. His
favorite hobby is to watch late night TV and snack on potato chips. Two weeks after his
checkup, Toby’s doctor called him and said that he was worried about Toby’s risk factors for
heart disease. The doctor warned Toby that his LDL cholesterol was 145 mg/dl, his
hemoglobin A1C was 8.8%, his blood pressure was 160/100, and his hsCRP (a measure of
inflammation) was 6.6 mg/L. All of these values are significantly above normal levels. The
doctor advised Toby to have a coronary calcium heart scan as soon as possible. Toby
wondered why the doctor was so concerned about risk factors when he felt fine and had no
pain in his chest, even with climbing stairs. Should Toby ignore his doctor’s advice?
Comment
Toby needs to realize that his heart disease started when he was an infant and has been
progressing ever since. Sooner or later it will catch up to Toby, as it will to everyone with
significant risk factors. If it takes 200 years to catch up with you, it obviously will not be a
problem. However, if it becomes manifest when you are 40 years old, your health and life span
may be greatly shortened. So what determines how rapidly heart disease progresses? To a
great extent, atherosclerotic risk factors are the determining factors.
There are numerous potential risk factors for heart disease, but the most important ones
include 1) a family history of heart disease, 2) smoking, 3) diabetes, 4) hypertension, and 5)
high blood cholesterol (LDL) levels. More recently, inflammation has been added to this list.
Studies have demonstrated that the more risk factors you have, the faster your heart disease
progresses. The way that these risk factors increase heart disease is to damage the internal
lining of the heart’s blood vessels (called the endothelial layer), increase inflammation, and add
LDL cholesterol to the heart’s coronary artery plaques. Controlling these risk factors (such as
stop smoking), will decrease the rate at which heart disease progresses (or better yet, it may
even reverse heart disease). It is a good bet that Toby’s coronary artery calcium score will be
dangerously high. He needs to greatly improve his lifestyle and take medication to reduce his
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blood pressure and hypercholesterolemia. If he does not take the doctor’s advice seriously, he
probably will not live to see his 60th birthday.

Figure legend – Illustrations of major risk factors for heart disease. Each of these risk factors
contribute to the increase in the rate at which heart disease develops. Many of these risk
factors can be reduced or eliminated with improved lifestyle and medications. On the other
hand, ignoring them usually results in a catastrophic heart attack. Have you monitored your
risk factors lately?
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Chapter H2: How do we know what constitutes risk factors?
Clinical Vignette
Paul McAndrew is a 47 year old high school teacher who teaches his students to do critical
thinking about facts and to avoid unproven myths. When he was waiting in his doctor’s office,
he picked up a flyer that said that age, hypertension, diabetes, smoking, and high blood fats
were all important risk factors for heart disease. As he read about it, he noticed that the article
suggested that he should change his life style to reduce his risk, but it contained no evidence
that these five items increased heart disease. When he discussed this article at the dinner
table that evening, his 15 year old son told him he was passing around “Fake News.” Paul
thought he should ask his doctor for additional facts about risk factors and the proof supporting
their validity.
Comment
Paul asked his doctor an excellent question, i.e., what is the basis for risk factors causing heart
disease? The answer goes back to the history of public health in the town of Framingham,
Massachusetts. In 1948 the National Heart Institute decided to identify common factors or
characteristics that contribute to heart disease. So they enrolled all the men and women in the
town of Framingham between the ages of 30 – 62 years who had no signs or symptoms of
heart disease. They followed them for 10 years to allow the prediction of the 10 year risk
(prediction) of developing heart disease. This study has been continued by adding all next
generations and spouses, with the latest groups starting in 2016. They recorded who
developed heart disease and when and whether any of the common factors or characteristics
that they identified were present. Thus, the term “risks factors” was used to describe these
common characteristics that predict heart disease.
This is exactly how the daily weather channel predicts tomorrow’s rain, snow, or sunshine.
They consider whether the clouds, wind, temperature, and other factors have appeared from
satellite information, put them into a computer, and the computer prints out a prediction of risk
for bad weather for tomorrow. Usually it is correct, but sometimes other unknown factors
change the outcome. This is similar to predicting risk factors for heart disease.

74

Relative to heart disease, we now have 15 years of prediction of heart attacks from coronary
artery calcium heart scans. We have found that adding the calcium heart scan to the
Framingham list of risk factors provides the best prediction of who is at risk for developing
heart disease (you can do this yourself by going to the MESA website at this link:
https://www.mesa-nhlbi.org/MESACHDRisk/MesaRiskScore/RiskScore.aspx. Surprisingly,
only the calcium heart scan proves you actually have heart disease, while the rest of the
factors are predictions, like tomorrow’s weather. You should take responsibility for identifying
your risk factors and follow your doctor’s advice in reducing them. As the title of this book
suggests, only you can save your heart. Risk factors are not “Fake News,” they are based on
real data, available to everyone.

Figure legend – Cardiac risk factors are an important cause of heart attacks. Some are not
preventable such as male gender, advancing age, and genetics. However, several risk factors
are preventable including diabetes glucose control, hypertension, smoking, and LDL
cholesterol. Studies have shown that 50% of heart attacks are due to uncontrolled risk factors.
Are you addressing yours?
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Chapter H3: Why is the Risk/Benefit ratio important to my heart?
Clinical Vignette
Charlie Matia is a 65 year old retired auto worker who loves to watch professional football. He
is an avid reader of the local paper’s sports page and makes small bets on his favorite team,
the Denver Broncos. He is in general good health and feels well except when he exercises,
which occasionally causes him chest pain. His physician ordered a coronary calcium heart
scan and the results demonstrated a score of 1,840. His physician then prescribed a statin
medication and told Charlie that the medication’s risk/benefit was strongly in favor of benefit.
Charlie left his doctor’s office wondering what the risk/benefit had to do with his heart.
Comment
Charlie may not realize it but he uses the “risk/benefit” ratio many times every day to make
decisions. For example, when Charlie walks across a street, he is unconsciously calculating
the benefit of being on the other side of the street against the risk of being hit by a car or truck.
If the risk exceeds the benefit (e.g., crossing an interstate highway at rush hour), Charlie will
choose another way to cross the street. When Charlie bets on the Denver Broncos, he is using
the risk/benefit ratio to determine what odds to give his friends that the Broncos will win. He
will try to maximize the benefit (of winning money) and minimize the risk (of losing money).
When Charlie’s doctor stated that the risk/benefit ratio of the prescribed statin was strongly in
favor of benefit, he meant that any side effects of the medication were far less important than
the benefit Charlie’s heart would get from the effects of the medications. More specifically, the
medication would prevent Charlie from having a heart attack vs. the unlikely chance that his
blood sugar might go up a small amount. Every study that has been done that has tested
statin therapy has concluded that the benefit of the drug is much greater than the risk of taking
the drug (even in people with no chest pain). Thus, most people reading this paragraph would
encourage Charlie to take his statin and ezetimibe medication.
In the real world, however, people don't always make the healthy risk/benefit decision and
simply quit taking their medicine. For example, 50% of people like Charlie are no longer
compliant about taking their statin medication after two years, for no particular reason and in
spite of the fact that it could save their life. Similarly, compliance with medication for high blood
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pressure falls into the same category of non-compliance, in spite of the fact that hypertension
is one of the critical risk factors causing heart disease. The same can be said for taking
diabetes medication. It should be remembered that atherosclerosis is a preventable/reversible
disease but only if patients follow the correct risk/benefit ratio and take their medications as
prescribed.

Figure legend – Treatment is indicated when the risk/benefit ratio is in favor of benefit. Statin
and ezetimibe therapy are almost always indicated when the individual has a positive coronary
artery calcium score and he/she is not at the goals of an LDL cholesterol of less than 50 mg/dl
and the C-reactive protein (hsCRP) of less than one.
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Chapter I1: What if Statins cause me Muscle Aches?
Clinical Vignette
Sandra Jacoby is a 48 year old secretary in a large corporation. She has had type 1 diabetes
for 12 years. Her diabetes has been under very good control with a hemoglobin A1C of 7.0.
Her hypertension is also well-controlled with a morning blood pressure of 130/90. On the
advice of her physician, she had a coronary artery calcium scan last week and the results
demonstrated a score of 430. She was not surprised by this high score because her LDL
cholesterol is 130 mg/dl. This level of LDL was probably inherited from her father, who had a
heart attack at age 44 years. Her physician recommends that she start medical therapy (10
mg/day of rosuvastatin and 10 mg/d of ezetimibe) to reduce her risk of having a heart attack.
However, she does not want to start a statin because she remembers being prescribed a statin
five years ago and it caused her muscle aches. What should she do?
Comment
Sandra’s concern is understandable and a common complaint of people prescribed a statin.
What are the facts? First, statins can cause muscle aches. From studies in which volunteers
were given either a statin or a placebo (that is, a dummy pill), the incidence of muscle aches is
one in 2,000 people on a high dose of a statin (thus, it is rare). Second, the side effects of
statins are dose dependent. That means that the higher the dose of the statin, the more likely
the chance of muscle aches. Third, muscle aches are very common in people not taking
statins (we can bet that you can remember times when you had aches and pains in your
muscles from exercising or carrying heavy objects). Fourth, when people who say they get
muscle aches from stains are rechallenged with a statin or a placebo, they almost never can
tell which medication was the statin. Thus, we would bet Sandra 2,000 to one (our $2,000
against her $1) that Sandra does not get muscle aches from a low dose of a statin.
What should her doctor do? Because Sandra is convinced that she gets muscle aches from
statins, her doctor should prescribe a very low dose (5 mg) of rosuvastatin once a week and
see if Sandra has any side effects. Trust us – she won’t. He should then slowly increase the
frequency of the medication to twice per week, then three times per week, etc. When she is
taking 5 mg/day of rosuvastatin each day, he should slowly increase the dose to 10 mg/day.
This is still a very low dose of rosuvastatin. There is rarely any need to raise the dose above
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10 mg/day as long as she also takes ezetimibe (which never causes muscle aches). This is
the approach we take in our clinic and we have never had a patient not being able to take 10
mg of rosuvastatin and 10 mg of ezetimibe, once per day.

OUCH !

Figure legend– Many activities cause muscle aches. It is very, very unusual for statins to
cause muscle aches compared to the myriad of activities of daily living that do. If you think
statins cause you muscle aches, try a very low dose of rosuvastin (5 mg) once a week and see
if they occur. The chances are less than one in two thousand that they will!

83

Chapter I2: Do statins cause diabetes?
Clinical Vignette
Mathew Sparks is a 50 year old package delivery worker for FedEx. He has a positive family
history for heart disease with both one sister and his father suffering a heart attack at an early
age. His LDL cholesterol is 134 mg/dl, his CRP is 4.6 mg/L, and his calcium heart score is 677
(high risk for a heart attack). Unfortunately, he also has a strong family history of diabetes,
with two brothers and one sister having type 2 diabetes. Their diabetic complications include
eye, kidney, and peripheral nerve disease. Mathew refuses to take a statin because he was
told it causes diabetes. Mathew wants to know “What should I do?”
Comment
Mathew asks a question that many people ask who are concerned about taking statins. They
want to know if they are substituting one serious disease (heart disease) for another (diabetes).
The answer is not complicated but does require an explanation. First, one of the several
definitions of diabetes is a fasting morning blood sugar concentration greater than 126 mg/dl.
Second, statins may raise fasting blood sugar about 8 mg/dl. Therefore, if a person has a
fasting blood sugar of less than 100 mg/dl, statins will raise that blood sugar to 108 mg/dl
(nowhere near the diabetes range). However, if a person has a fasting blood sugar of 120
mg/dl, than statins would push that person into the diabetic range. Note that statins will never
cause diabetes in a normal (non-diabetic or non-prediabetic) person. Third, the effect of statins
on blood glucose is related to the dose of a statin. A recent study has shown that 10 mg/day of
rosuvastatin does not raise blood glucose but higher doses may. This is the reason that we
recommend 10 mg/day as the optimal dose of rosuvastatin. Fourth, if higher doses of
rosuvastatin are required (rare), then a small dose of an antidiabetes medication will cancel the
statin’s effect on blood glucose. Fifth, every study that has examined the risk of diabetes from
taking a statin versus the benefit of that statin in reducing heart disease has concluded that the
benefit far outweighs the risk of the small elevation in blood sugar caused by the statin.
Therefore, to answer Mathew’s question, he should definitely be on triple therapy by taking 10
mg/day of rosuvastatin (plus 10 mg/day of ezetimibe plus 81 mg/day of aspirin) to save his
heart. Keep in mind that the small rise in fasting blood sugar is easy to treat. In contrast, a
heart attack is difficult to treat (assuming that Mathew lives long enough to get to a hospital).
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Figure legend – The risk of a heart attack far outweighs the risk of any small increase in blood
sugar. The first may kill you, the second never does. The first is difficult to treat since dead
heart muscle cannot be restored. The second is easy to treat with a small dose of diabetes
medication. A low dose of 10 mg/day of rosuvastatin does not raise blood sugar but does save
lives and prevents heart attacks.
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Chapter I3: Statin side effects – fiction versus truth?
Clinical Vignette
Kathy Corelli is a 51 year old librarian whose father had a heart attack at age 49 and a mother
who died of heart failure after a massive heart attack at age 52. During her last health
checkup, her doctor strongly recommended a statin medication to lower her elevated LDL
cholesterol. He warned her that she was at high risk because of her positive family history for
heart disease and an elevated LDL cholesterol. She agreed to think about taking a statin but
her best friend warned her, “Beware - statins cause dementia and cataracts!” What should
she do?
Comment
We have one piece of advice for Kathy: consider the facts. The popular press and the internet
is full of bad advice about statins. In contrast, there are many good scientific studies assessing
the side effects of statins. Here is a list of the claimed side effects of statins and conclusions of
experts based on scientific evidence.
1) Statins cause cataracts – Many studies looking at this potential side effect have concluded
that there is no good evidence that they do. Cataracts are a natural result of aging, so this
occurrence is sometime confused with a side effect of statins.
2) Statins cause dementia – Many studies have examined this question. There are just as
many studies that show that statins prevent dementia, as may be a cause of it. What is certain
is that statins prevent atherosclerotic strokes that can lead to dementia. Statins do not cause
Alzheimer’s disease.
3) Statins cause liver disease – This potential side effect used to be a concern, but now the
FDA says it occurs so rarely that the doctor should not even bother to monitor for it.
4) Statins cause muscle aches – There is a specific chapter on this issue. Suffice it to say
that statin-caused muscle aches are rare. Serious muscle disease is only seen in individuals
on very high statin dosages who are also taking other drugs that interfere with statin
breakdown. It does not occur with the low dosages of statins (10 mg/day) plus ezetimibe that
we recommend.
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5) Statins cause diabetes – There is a specific chapter on this issue also. Statins at high
dosages (>20 mg /day) may result in diabetes but not at low dosages. When the risk/benefit
ratio was considered, for every one case of diabetes that occurred, five heart attacks were
prevented. Diabetes can be treated with medication, but heart attacks kill 50% of people
before they even get to the emergency room. No diabetes was observed when 10 mg of
rosuvastatin was prescribed.
If the side effects of statins are rare, why do so many people complain of side effects when
they take statins? There are at least two reasons that people complain. First, it is human
nature to want to blame a pain or event on some identifiable reason. The easiest reason is to
blame a medication instead of some natural phenomenon such as aging. We are all guilty of
doing this. Second, when we hear or see someone state that statins cause many side effects,
we assume it must be true and apply it to ourselves. The English word for this phenomenon is
“nocebo”. The best protection against this false impression is to ask for the proof of causation.
Scientific studies provide the best proof of causation. Kathy should take a low dose of a statin
(10 mg) plus ezetimibe (10 mg) and she will not experience any statin side effects.

Statin
s

Figure legend – all medications have side effects, some more, some less. What is important
is whether the health benefits of the medication greatly outweigh the risks. All credible
scientific studies show that the benefits of statins greatly outweigh the risks. Would you rather
have a heart attack than a small increase in your fasting sugar concentration? You can treat
the latter, if necessary, but the former may kill you.
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Chapter J1: What is this new drug called ezetimibe?
Vignette
Abel Alexander is a 38 year old insurance salesman who is going to college in the evenings to
obtain a Masters of Science degree. His current course on major diseases affecting the U.S.
population includes the epidemiology and treatment of cardiovascular disease. His textbook
includes a description of statin therapy but no mention of ezetimibe (Zetia®). His textbook was
published only three years ago so he assumes that it is up-to-date. Abel wants to know why
his textbook does not mention ezetimibe and “What does this drug do?”
Comment
We are not surprised that Abel’s textbook does not include ezetimibe as a recommended
treatment for cardiovascular disease. Textbooks require several years of writing and editing
before they are ready for printing. They then need to be distributed to bookstores and sold, a
process which may take many months. In a field such as medicine in which new therapies are
being approved by the Food and Drug Administration almost monthly, it is impossible for
textbooks to include recently available medications.
Ezetimibe (brand name Zetia®) has actually been available for many years but not for the
treatment of cardiovascular disease. It was an excellent therapy for a rare genetic disease
called sitosterolemia in which the intestine absorbs too many plant sterols. This raises blood
cholesterol levels and results in the early onset of cardiovascular disease. Ezetimibe blocks
the intestinal cholesterol receptor, which absorbs both cholesterol and plant sterols. By
blocking the cholesterol receptor, the absorption of plant sterols are also blocked and the
sitosterolemic patient’s outlook is much improved.
It was not until 2015 that a very large clinical study of the use of ezetimibe in combination with
statin treatment was demonstrated to significantly reduce cardiovascular disease. This
milestone clinical trial required 7 years to complete and involved 18,000 patient volunteers.
Since this time, many other studies have been done demonstrating that ezetimibe reduces
circulating LDL cholesterol about 20 to 25%. The maximum effect of this drug occurs at a dose
of 10 mg/day, and that is the only dose commercially available. Ezetimibe should always be
used in conjunction with a low dose of a statin medication (i.e., rosuvastatin) because they
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work very well together to lower LDL cholesterol. Ezetimibe also reduces triglycerides and
raises HDL cholesterol, but its beneficial effects are thought primarily to be due to LDLc
lowering. Ezetimibe is available as a generic medication at a very inexpensive price. Although
it blocks 50% of cholesterol absorption, it causes no intestinal side effects, since it does not
block other types of fat absorption.

Figure legend – Ezetimibe blocks cholesterol absorption in the intestines, a process which
results in less cholesterol going to the liver. When statins also block the production of
cholesterol by the liver, the net result is much less cholesterol available to the liver to make bile
acids. Bile acids are secreted by the liver into the intestine to help digest fats. When the liver
needs more cholesterol, it increases the LDL receptors on its surface, which in turn removes
LDL cholesterol from the blood, lowering the level of circulating LDL cholesterol. Thus,
ezetimibe works very well with statins to help individuals achieve their LDL cholesterol goal of
<50 mg/dl.
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Chapter J2: Aspirin – The last word?
Clinical Vignette
Thomas Franklin is a 66 year old retired farm worker. He has known heart disease, having had
a stent placed in one of his coronary arteries three years ago. His family doctor prescribed a
first-generation statin to lower his LDL cholesterol. It decreased from 125 mg/dl to 90 mg/dl.
His doctor retired last year, and he was assigned a new physician recently graduated from
medical training. When he saw this doctor, she recommended changing his medication to a
more powerful statin (rosuvastatin 10 mg/day) plus adding ezetimibe 10 mg/day and low dose
aspirin 81 mg/day. She was also concerned that Thomas’ hsCRP was elevated at 3.6 mg/L,
indicating excess inflammation. He understands that the rosuvastatin and ezetimibe will
significantly lower his LDL cholesterol further. However, he wants to know what purpose
aspirin serves.
Comment
Aspirin is a medication that has been used for many years to treat arthritic pain and fever. Its
benefits and side effects are well known. More recently, it has been recommended to prevent
heart attacks in individuals with significant risk. It is inexpensive and does not require a
physician’s prescription. Studies have shown that it works well in combination with statins to
reduce heart attacks and strokes.
Aspirin has two major beneficial effects in man. First, it reduces inflammation throughout the
body. It does this by blocking several chemical reactions in the body. As discussed in another
chapter, inflammation is a necessary contributor to the development of atherosclerotic plaques.
Specifically, inflammation enhances the movement of macrophages (white blood cells) into the
coronary arteries and ingesting LDL cholesterol particles to form a fatty streak. These fatty
streaks develop into unstable plaques, which can rupture into the coronary artery lumen (see
figure). A blood clot forms around this rupture and obstructs the coronary artery, causing a
heart attack. Aspirin’s inhibition of inflammation will help prevent these unwanted events.
The second beneficial effect of aspirin is to inhibit the formation of blood clots. It does this by
blocking the ability of blood platelets to clump together, which is the initial stage of a blood clot.
Without a blood clot, it would be unusual for a ruptured plaque to obstruct a coronary artery.
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Since this activity of aspirin is different from that of statins and ezetimibe, its beneficial effects
add to those of these medications.
The ability of aspirin to block the formation of blood clots does have a down side – that is, in
about 4% of people, it can cause excessive bleeding from cuts, bruises, and other traumatic
events. However, this side effect can be minimized by not taking a dose greater than 81
mg/day and restricting its use to people at high risk for heart disease. In this category are
people with a history of known heart disease (such as Franklin) and anyone with a coronary
artery calcium score above 100. We also recommend not using aspirin in anyone over the age
of 75 years because of increased risk of falling and bruising. We also recommend stopping
aspirin after the LDL cholesterol has been 50 mg/dl or less for at least two continuous years
because by the end of two years, atherosclerotic plaques should be stabilized. In the case of
Franklin, we would recommend that he start triple therapy as soon as possible (rosuvastatin
10mg/d, ezetimibe 10 mg/d, and aspirin 81 mg/d).

Figure legend – Rupture at the side of an atherosclerotic plaque causing platelets (blue
particles) to clump, plugging the tear in the artery wall with blood cells (red) that form a blood
clot. If the clot is large enough, the artery is blocked, resulting in a heart attack. Aspirin can
help prevent this clot.
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Chapter J3: Is low dose statin plus ezetimibe better than a high dose statin?
Clinical Vignette
Margaret Vazquez is a 45 yr old mother of two children, who thought herself perfectly healthy
until one afternoon when she suddenly developed acute chest pain, sweating, rapid heartbeat,
and severe pain in her left arm extending into her jaw. The emergency room quickly confirmed
an acute heart attack. Her cardiologist prescribed 80 mg of Lipitor® (atorvastatin) to reduce
her LDL cholesterol.

She had a friend whose husband had a similar experience, and his

doctor started him on a much lower dose (10 mg/day) of a statin called (rosuvastatin) as well
as a low dose of a second pill called ezetimibe. Margaret wants to know why her friend’s
doctor put her husband on ezetimibe plus a low dose of the rosuvastatin.
Comment
Margaret asked a very good question and one which some doctors do not appreciate. All
brands of statins block the liver’s production of cholesterol at the same metabolic step.
However, statins differ in their potency to lower the liver’s cholesterol production. The most
potent statin is rosuvastatin, which is up to four times more potent than Lipitor (atorvastatin).
Ten mg of rosuvastatin has about the same LDLc lowering effect as 40 mg of atorvastatin.
That is one reason that we recommend rosuvastatin as the best statin to use (all statins are
available in a generic formulation). The other reason is that as the dose of a statin is
increased, only a small benefit is achieved. The reason for this unusual result has only
recently been discovered. It is a protein called PCSK9 (we agree this is a crazy name).
Statin medications block the liver’s production of cholesterol. Unfortunately, the liver reacts to
this blockage by producing PCSK9 protein. This protein destroys the liver’s LDL receptor so
that the liver can no longer clear the blood of LDL cholesterol. The result is to blunt the statin’s
ability to lower blood LDL cholesterol. The higher the dose of a statin, the more of this harmful
protein is made. This is why high doses of atorvastatin are not much better than low dosages
of atorvastatin. To put this concept in perspective, 75% of a statin’s ability to lower LDLc is
achieved at the 10 mg dose and only a 6% beneficial effect is seen when the dose is doubled
(This is called the 6% rule).
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The way your doctor can fool the liver is to add a second drug to the patient’s regimen that
works at a different place other than the liver. Ezetimibe does just that, by blocking cholesterol
absorption at the intestine. Thus, the best approach to lowering LDLc is to combine a low dose
of rosuvastatin with a low dose of ezetimibe (10 mg).
Remember that the side effects of statins are dose related. The higher the dose, the more side
effects (these side effects do not follow the 6% rule). Therefore, if the physician wants to
achieve the maximum lowering effect of statin drugs with the least amount of side effects,
he/she will prescribe a low dose of the combination rosuvastatin and ezetimibe. Margaret
needs to discuss this approach with her cardiologist if she wants the best treatment possible
for preventing another heart attack.

Figure legend – Ezetimibe blocks the absorption of cholesterol consumed from food. It works
hand-in-hand with rosuvastatin to block the liver’s production of cholesterol. Side effects are
very, very rare. This is an excellent combination of medications to save your heart by lowering
your LDL cholesterol level.
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Chapter J4: What is Great About Triple Therapy for Heart Disease?
Clinical Vignette
Mark Cannon is a 50 year old heavy equipment operator who is proud of the fact that he takes
no medications to stay healthy. He feels great, smokes 2 packs of cigarettes/day and is
significantly overweight. During his last annual physical exam (a job requirement), his doctor
suggested a coronary artery calcium scan because of his cardiovascular risk factors. “No
problem,” he thought until his calcium heart scan detected calcium in his heart’s arteries,
resulting in a final score of 988. The doctor recommended losing weight, improving his lifestyle
with exercise three times per week, and triple medication therapy to counteract his elevated
LDL cholesterol (145 mg/dl) and elevated inflammation (hsCRP = 3.5 mg/L). He grudgingly
agreed but asked, “Why three medications? Won’t one do the job?”
Comment
Mark asked a good question, “Why triple therapy?” The answer is that prescribing any
medication is a balance between good and bad (often called the “Risk/Benefit ratio”). In Mark’s
case, the physician wants to maximally reduce his LDL cholesterol level (to < 50 mg/dl) and
inflammation level (hsCRP to <1.0 mg/L) without causing major side effects (diabetes and
muscle aches from statins and bleeding from aspirin). For many medications (including statins
and aspirin), the occurrence of side effects is dose dependent (the higher the dose, the more
the side effects). Although this may sound counterintuitive, the benefits of medications are not
always dose dependent. For statins, 75% of the benefit is achieved at the lowest dose (10
mg/day of rosuvastatin). Doubling this dose only achieves a 6% increase in benefit (often
called 6% rule), so keeping the dose low to avoid side effects is a wise approach. At high
dosages, statins can raise blood sugar and may cause diabetes. This is also true for muscle
aches. These side effects are rarely, if ever, seen at the 10 mg dose of a statin. For
ezetimibe, there is only one dose available (10 mg/day), so dose response is not question.
Ezetimibe has almost no side effects when used with a statin but it does greatly improve
statin’s ability to lower LDL cholesterol by blocking intestinal cholesterol absorption. For
aspirin, the lowest dose (81 mg) is also recommended, since no added benefit in lowering
inflammation has been observed in clinical trials with higher dosages. In contrast, higher
dosages of aspirin do cause more bleeding.
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Triple therapy (albeit different medications) is also used to treat other diseases (for example,
diabetes and hypertension) in order to maximize benefits and minimize side effects. For
atherosclerosis, triple therapy is definitely indicated, and Mark should recognize that it is to his
benefit that all three medications were recommended by his physician. He also needs to
accept the fact that improved lifestyle and triple therapy will likely save his life. Keep this
approach in mind the next time your health caregiver prescribes medication for you.

Figure legend #13 – A coronary artery calcium score above 100 is best treated with triple
therapy. This approach will maximize the benefits of the drugs while minimalizing their side
effects. If you are on a statin only and not at your LDL or hsCRP goal, you should request
triple therapy from your doctor. Triple therapy consists of rosuvastatin 10 mg/d, ezetimibe 10
mg/d, and coated low dose aspirin 81 mg/d.
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Chapter J5: With triple therapy, when will my heart calcium disappear?
Clinical Vignette
Agnes Moore is a 60 year old mother of two children and three grandchildren. She takes many
herbal medications that she buys at the health food store. She recently had a coronary artery
calcium scan and her score was 665. She was started on triple therapy (rosuvastatin 10 mg,
ezetimibe 10 mg, and aspirin 81 mg, all once per day). On this therapy, her LDL cholesterol
dropped to 45 mg/dl and her hsCRP to 1.3 mg/L. She would like to know how long it will take
to get rid of the calcium in her heart arteries so that her calcium score is zero and she can stop
her medications.
Comment
It will probably come as a surprise to Agnes that the calcium in her heart is actually beneficial
to her. Her body deposits calcium in atherosclerotic plaques to stabilize them and prevent
them from rupturing into the arterial lumen. Think of the body’s defenses as isolating a foreign
invader (an atherosclerotic plaque) by walling it off to prevent it from doing damage. The most
dangerous plaques are those with no calcium in their walls. They are the most likely to rupture
into the arterial lumen. Agnes should appreciate that triple therapy does not reduce the
calcium in her plaques. In fact, one way that statins prevent heart attacks by stabilizing
plaques is to increase the calcium in atherosclerotic plaques. Therefore, Agnes can expect a
slow increase in her coronary artery calcium score as her plaques become more stabilized.
Her score will never return to zero. The calcium does not prevent the removal of cholesterol
and inflammation from the plaque, so eventually when all the plaques are removed by triple
therapy, the calcium will still be there. It is not harmful but a good reminder of the danger of
elevated LDL and inflammation.
Agnes should also remember that atherosclerosis is a chronic disease which started when she
was an infant and will continue until she dies. If she stops therapy, she will then return to her
previous state of increasing atherosclerotic plaques and be at risk for heart attacks. As long as
she is having no side effects from the medication, we would advise her to continue triple
therapy. Of course, if she needs surgery or some other medical intervention, she can always
stop the therapy for short intervals of time. Once she has been on triple therapy for two years
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with her LDL below 50 mg/dl, she can stop the aspirin since her plaques should be stabilized
and reversing.

Figure legend – A coronary artery calcium scan identifies calcium in the atherosclerotic
plaque. This is a sensitive way of quantifying your risk of future heart attacks. However, this
does not mean that the calcium is harmful. Studies demonstrate that plaques without calcium,
which are not seen on a coronary artery calcium scan, are more likely to rupture and cause
heart attacks. Depositing calcium in the arteries is one way that your body protects you.
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Chapter K1: Should I ask my relatives to be screened for Heart Disease?
Clinical Vignette
Lisa McKinney is a 55 year old clerk at a local grocery store. She has a large family with three
sisters and four brothers. Her grandfather had heart disease (type unknown) and her mother
had a stroke in her early 60’s. She read about the benefits of a coronary artery calcium scan in
Time magazine, so she asked her doctor to order it. Her score was 377 and her doctor started
her on triple therapy to reverse the atherosclerotic plaques in her heart. Lisa would like to
know if she should talk to her relatives about the benefits of the scan and what criteria they
should meet to be scheduled for a calcium heart scan.
Comment
The issue concerning who should be screened for heart disease with a coronary artery calcium
scan is important. There is no reason to scan someone who you know will have a positive
scan or someone you know who will have a negative scan. For this reason, we do not
recommend screening anyone with known atherosclerotic heart disease (e.g., they have
already had a heart attack). The reason is that their scan will almost always be positive. Using
the same line of reasoning, we do not recommend screening anyone with absolutely no risk
factors for heart disease (this is very rare because major risk factors include diabetes,
hypertension, abnormal blood fats, age greater than 50 years, and smoking, whereas minor
risk factors include obesity, positive family history of heart disease or stroke, male gender,
kidney disease, insulin resistance, and several inflammatory diseases. Therefore, the majority
of asymptomatic adults should be screened.
The next question is at what age people should be screened. Since many individuals have
heart attacks in their 40’s, screening after age 40 may be too late. Here is our
recommendation. If an adult has more than one major risk factor, we recommend coronary
artery calcium screening after the age of 30 years. If a person has only one major risk factor,
we recommend screening after the age of 40 years. Since age is a major risk factor for
atherosclerosis, everyone who has not been screened by the age of 50 years should be
screened. We don’t believe that anyone is too old to be screened as long as they are relatively
healthy (a projected lifespan of at least 5 years) and a situation in which a heart attack would
be detrimental to their wellbeing.
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Coronary artery calcium scanning is a much under-utilized diagnostic test in the United States.
Remember that it is noninvasive and reasonably priced. There are not many tests that have
these two characteristics that can save your life. It is much better to be scanned and have a
zero score than not to be scanned and have a heart attack. Wouldn’t you agree?
To answer Lisa’s question, she should communicate the above criteria to her relatives and
recommend a scan for any of them who meet the age and risk categories. She will be doing
them a great favor and they should appreciate her caring for their health.

Figure legend – Who should receive a coronary artery calcium scan and when to recommend
this scan depends upon a person’s age and the number of cardiovascular risk factors. The text
above gives our recommendations for whom to scan. However, if a person is anxious about
the possibility of heart disease, we recommend a scan to set that person’s mind at ease.
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Chapter K2: What information can I believe from the Internet?
Clinical Vignette
Frank Spafford is a 39 year old executive in a small family owned business that relies on the
internet for customer orders. He is computer savvy, spending much of his time sitting in front
of a computer monitor. He also has type 2 diabetes, hypertension, obesity and a strong family
history of heart disease. He wants to avoid the fate of his father who died at age 48 of a heart
attack and a 46 year old brother who is currently in the hospital with heart failure. When he
uses the internet to get information on preventing heart disease, he gets confused because of
the many conflicting recommendations. He asks “What should I believe on the internet?”
Comment
We sympathize with Frank’s dilemma. How should he go about separating the valid
information from the false information on heart disease? We can make four recommendations
that should help Frank decide what information to believe.
1) Does the author of the information have a vested interest in your believing that their
information is real? If so, beware!! For example, the dairy industry has a vested interest in
your thinking that dairy products do not raise cholesterol. They want you to buy their eggs,
butter, and cheese. These products do raise your cholesterol level and should only be eaten in
strict moderation.
2) Does the author of the information have any recognized education and training in the area of
heart disease? You would be amazed about how many people believe they are experts on any
subject after they have watched a five minute video on YouTube! Authors that have expertise
should always tell you their credentials (if they have any). Just because the website looks
professionally made does not say anything about the validity of the information on it.
3) Does the author of the information have a product to sell to you directly online? Scams on
the internet are legendary. “Buyer beware” is an axiom which you should always keep in mind.
Many people believe that if something is written, it must be true. Nothing is farther from the
truth.
4) Is the information based upon scientifically proven facts or just hopeful studies which have
not been published in scientific journals? Seeing it on TV or in a newspaper advertisement
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does not give it validity. In addition, it is often very difficult for the lay person to understand all
the technical jargon that is used in scientific papers. However, asking a friend with expertise in
the area of the information is a good start. Many universities and hospitals have
knowledgeable professionals whom you can ask.
To summarize, there is valid information on the internet. However, sifting through all the bogus
information is not easy. We sympathize with Frank’s dilemma but if he follows our advice, he
has a good chance of separating good information from bad information.

Figure legend – The internet is full of contradictory information. Often, the reader can’t tell
who is writing the information and what they stand to benefit from your believing it. The rule
“Don’t believe all you read” is certainly applicable to internet information.
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Chapter K3: Who’s got your numbers?
Clinical Vignette
Frank Beal is a 52 year old salesman who covers a 5 state area selling wholesale business
furniture to small companies. On a recent trip to Arizona, he developed chest pain and diffuse
sweating. A business colleague brought him to an emergency room for treatment. The
emergency room physician asked Frank if he knew what his previously performed heart tracing
showed (electrocardiogram) as well as his recent calcium heart scan score, lipid profile, and
hsCRP concentration. Frank responded that he had no idea what his previous health values
were. His own physician’s office was closed for the weekend. The emergency room physician
was disappointed and indicated that he would need to repeat all of these tests at significant
expense to Frank. In addition, Frank was hospitalized overnight because the physician was
nervous about Frank’s chest pain.
Comment
Frank should have realized that an important part of taking care of one’s health is knowing the
results of his/her recent medical tests in case they are urgently needed. One of the major
deficiencies of the U.S. health care system is the inability of physicians to access other
systems’ medical databases. There are several reasons for this lack but the primary reason is
that hospital administrators are bound by strict HIPAA regulations to safeguard patients’
medical data. It is unlikely that this problem will be resolved soon. Therefore, patients need to
be able to inform physicians what their medical test results are. A good place to store these
numbers is on your cell phone.
One of the more beneficial advances in medical record keeping is the development of patient
portals. Almost all major healthcare systems now permit patients to access their own medical
records. This is usually done by signing up with the healthcare system and providing a unique
password for access to your medical records. All patients should sign up for access to their
portal and print out all the tests that have been done in the last year. Critical results, such as
records related to heart health, should be carried with the patient or be otherwise accessible if
he/she is going to travel out of town. This approach is very easy to do now that cell phone
cameras are widely available. Taking a picture of all important lab results is a great way to
have ready access to your data.
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Relative to heart health, we recommend that patients should have ready access to their
previous electrocardiogram (heart tracing), coronary artery calcium scan, lipid profile, hsCRP
and any previous medical description of chest pain. If Frank had taken our advice, he would
have saved additional expenses and avoided an overnight stay in the hospital. Think of the old
adage “a stitch in time saves nine.”

Figure legend – The above illustration shows has easy it is to save your own important
laboratory numbers. You can do this through your own patient medical record portal (ask your
clinic nurse for an application form). You should keep a permanent record of all of your critical
health results so that you can access them at any time. Not only is this good health care but it
will give you reassurance that medical tests will not be unnecessarily repeated.

113

K.
MY FAMILY AND HEART DISEASE
Citations
1. Bacha F, Edmundowicz D, Sutton-Tyrell K, Lee S, Fjayli H, Arslanian SA. Coronary
Artery Calcification in Obese Youth: What Are the Phenotypic and Metabolic
Determinants? Diabetes Care 2014; 37:2632–2639 | DOI: 10.2337/dc14-0193
2. Baker JL, Olsen LW, Sorensen TI. Childhood body mass index and the risk of coronary
heart disease in adulthood. Ugeskr Laeger 2008; 170(33):2434-2437.
3. Bao W, Srinivasan SR, Wattigney WA, Bao W, Berenson GS. Usefulness of childhood
low-density lipoprotein cholesterol level in predicting adult dyslipidemia and other
cardiovascular risks: The Bogalusa Heart Study. Arch Intern Med 1996; 156(12):13151320. doi: 10.1001/archinte.1996.00440110083011
4. Berenson GS. Childhood risk factors predict adult risk associated with subclinical
cardiovascular disease. The Bogalusa Heart Study. Am J Cardiol. 2002; 90(10C):3L-7L.
5. Cromwell WC, Otvos JD, Keyes MJ, et al. LDL Particle Number and Risk of Future
Cardiovascular Disease in the Framingham Offspring Study – Implications for LDL
Management. Journal of clinical lipidology. 2007; 1(6):583-592.
6. Daniels SR. Cardiovascular disease risk factors and atherosclerosis in children and
adolescents. Current atherosclerosis reports. 2001; 3(6):479-85.
7. Gidding SSRJ, Rana JS, Prendergast C, et al. Pathobiological Determinants of
Atherosclerosis in Youth (PDAY) risk score in young adults predicts coronary artery and
abdominal aorta calcium in middle age: the CARDIA Study. Circulation. 2016;
133(2):139-146.
8. Ho M, Garnett SP, Baur L, Burrows T, Stewart L, Neve M, et al. Effectiveness of lifestyle
interventions in child obesity: systematic review with meta-analysis. Pediatrics. 2012;
130(6):e1647-1671. doi: 10.1542/peds.2012-1176.
9. McMahan CA, Gidding SS, Malcom GT, Tracy RE, Strong JP, McGill HC Jr, et al.
Pathobiological determinants of atherosclerosis in youth risk scores are associated with
early and advanced atherosclerosis. Pediatrics. 2006; 118(4):1447-1455.

114

10. Morrison KM, Dyal L, Conner W, Helden E, Newkirk L, Yusuf S, et al. Cardiovascular
risk factors and non-invasive assessment of subclinical atherosclerosis in youth.
Atherosclerosis. 2010; 208(2):501-505. doi: 10.1016/j.atherosclerosis.2009.07.034.
11. Rewers M, Ehrlich J, Jensen L, Siegel R, Barriga K, Garg S, et al. High Prevalence of
Asymptomatic Coronary Atherosclerosis Detected by Electron Beam Computed
Tomography in Young Adults With IDDM. Diabetes. 1998; 47(1S):12A.
12. Ridker PM, Cook NR. Cholesterol Evaluation in Young Adults: Absence of Clinical Trial
Evidence Is Not a Reason to Delay Screening. Ann Intern Med. 2017; 166(12):901-902.
doi: 10.7326/M17-0855.
13. Schade DS, Murphy S, Exil V, Eaton P. A Pediatric Opportunity in Adolescents to
Prevent Adult Heart Attacks. World Journal Cardiovascular Diseases 2018; 8(2):85-101
doi: 10.4236/wjcd.2018.82009
14. Stary HC. Evolution and progression of atherosclerotic lesions in coronary arteries of
children and young adults. Arteriosclerosis Supplement I 1989; 9:I19 – I32
15. Tirosh A, Shai I, Afek A, Dubnov-Raz G, Ayalon N, Gordon B, et al. Adolescent BMI
Trajectory and Risk of Diabetes versus Coronary Disease. N Engl J Med 2011;
364:1315-1325.
16. Tuzcu EM, Kapadia SR, Tutar E, Ziada KM, Hobbs RE, McCarthy PM, Young YB,
Nissen SE. High prevalence of coronary atherosclerosis in asymptomatic teenagers
and young adults. Circulation 2001; 103:2705-2710.
17. Twig G, Yaniv G, Levine H, Leiba A, Goldberger N, Derazne E, et al. Body-Mass Index
in 2.3 Million Adolescents and Cardiovascular Death in Adulthood. N Engl J Med. 2016;
374(25):2430-2440.
18. Wald DS, Bestwick JP, Morris JK, Whyte K, Jenkins L, Wald NJ. Child–Parent Familial
Hypercholesterolemia Screening in Primary Care. N Engl J Med 2016; 375:1628-1637.
19. Wiegman A, Hutten BA, deGroot E, Rodenburg J, Bakker HD, Büller HR, Sijbrands
EJG, Kastelein JJP. Efficacy and safety of statin therapy in children with familial
hypercholesterolemia: A randomized controlled trial. JAMA 2004; 292(3)331-337.

115

Born in Kentucky and raised on the Missouri frontier, Kit Carson became an
experienced hunter and trapper by his 20s. After meeting explorer John C. Frémont in
1842, Carson was an active participant in extending the boundaries of the United
States to its present size. He became a federal Indian agent in the 1850s and later
served the Union Army in the Civil War. Carson, who died in Colorado in 1868, is
remembered as an icon of the frontiersman days of the American West. He is buried
near his home in Taos, New Mexico
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Chapter L1: Will my high HDL cholesterol protect me?
Clinical Vignette
Shelley Johnston is a 40 year old married woman with three children. She takes estrogen
medication to control the hot flashes that have occurred for the last three years. She is
overweight with type 2 diabetes. Her mother had a heart attack at age 46, so she is worried
that she also may be at risk. At her last routine medical checkup, her laboratory results
demonstrated an elevated LDL cholesterol (133 mg/dl) and an elevated hsCRP (6.0 mg/L).
However, her doctor told her not to worry, since her HDL cholesterol was also elevated (88
mg/dl). He said that the high HDL cholesterol cancelled out the harmful effects of the elevated
LDL and hsCRP. Shelley wants a second opinion about the safety of depending upon her HDL
to prevent a heart attack.
Comment
Shelley is right to seek a second opinion. HDL is a very small fat particle that is secreted from
both your liver and intestine into the blood. It has many functions in the body, but the main one
is to carry cholesterol from the arteries to the liver for disposal. In that role, it is responsible for
removing atherosclerotic plaques by reducing their quantity of cholesterol. It also has a
secondary role of reducing inflammation. Without these two activities, it is likely that we would
all have heart attacks at very young ages.
Studies of large numbers of people have demonstrated that the higher the HDL level is in the
blood, the less heart disease there is. These studies are undoubtedly what Shelley’s doctor is
referring to. However, it is also clear that the benefit of a raised HDL is different in different
people. That is because what is measured in routine blood tests is the concentration of HDL in
the blood, not whether HDL is actively removing cholesterol from atherosclerotic plaques.
Think of a train waiting at the station. You assume that it will take you from your town to the
next town but that assumes that the engine in the train has enough fuel or the engineer is
available to start the train. It’s the same for HDL. When the concentration is high, it is usually
beneficial, but not always. Studies have demonstrated that a high concentration of HDL does
not always mean a high level of cholesterol removal from plaques. Shelley is right to be
suspicious and she should not depend on her high HDL to protect her from a heart attack.
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Instead, she should obtain a coronary artery calcium scan and if positive, start treatment to
lower her LDL and hsCRP to reduce the rate that she makes atherosclerotic plaques.
In contrast to a high HDL blood concentration, a low HDL is usually a heart attack risk factor.
This fact is based on the observation that the HDL may be working but there is not enough of it
to keep up with the deposition of LDL cholesterol in coronary artery plaques. HDL is lowered
by smoking, obesity, and lack of exercise. This is one reason that these factors are risk factors
for heart disease.

Figure legend – Normally, HDL removes the cholesterol from atherosclerotic plaques that LDL
lays down in the coronary arteries. But just measuring the amount of HDL does not tell you
how hard HDL is working to remove the plaque cholesterol. It may be that LDL is depositing
twice the amount of cholesterol in your artery that HDL is removing. The point of this chapter is
not to rely on your HDL level to protect you from a heart attack. If you get a coronary artery
calcium scan and your score is zero, you know that your HDL is working at a high rate to
remove any plaques that your LDL is depositing in your arteries.
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Chapter L2: Is Cholesterol Good or Bad?
Clinical Vignette
Jesse Sanchez is a 40 year old high school teacher who is very interested in staying healthy.
He exercises regularly at the local gym three times a week and eats a healthy diet of
vegetables, fruits, plus lean meat and fish. He likes to use the internet for health advice but is
confused when trying to understand the role of cholesterol in his body. Some of the internet
blogs say cholesterol is good. Others say it is bad. What is the real story?
Comment
It is understandable that Jesse is confused. Many people are. So here are the facts. First,
cholesterol is a big molecule that is shaped like four intersecting rings. It is a very stable
molecule, which means that your body cannot break it up into smaller pieces. Once it is in your
body, it stays there until your liver excretes it into your gut for removal in the stool. Second,
every cell in your body can make all the cholesterol it needs. It is not necessary to consume
any in the diet. Your cells need some cholesterol to stabilize various structures in the cell,
particularly the membrane that forms the outside boundary of each cell. Think of a soap
bubble. If there were cholesterol in the soap, the bubble might never pop. Cholesterol is also
essential for stabilizing the outside of fat particles that circulate in your blood to carry energy to
your muscles. Finally, cholesterol is an essential component of bile acids, which are necessary
to digest the fat that you eat. For these functions, cholesterol is essential for life (cholesterol in
this role is good). Third, cholesterol can cause two diseases in humans – cholesterol stones in
your gall bladder and atherosclerotic plaques in your arteries. In these two roles, cholesterol
deposits can result in abdominal surgery, a heart attack, or stroke. Fourth, the cholesterol that
circulates in your blood comes from two sources: from your diet and from the cholesterol that
your liver produces. Fifth, only animals can make cholesterol. Plants do not manufacture
cholesterol (they use a different molecule to stabilize their cell membranes). This is the reason
that strict non-dairy consuming vegetarians eat much less cholesterol than individuals
consuming diets containing meat and dairy products. As a group, vegetarians have a much
lower amount of circulating cholesterol in their blood. As you would expect, they also have
fewer heart attacks.
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Therefore, to answer Jesse’s question, cholesterol is both good and bad. Too much causes
disease. Too little is not compatible with human life. We are sure you can think of many other
things in life for which too much of a good thing is bad (such as visits from your relatives). The
point to remember from this is that since every cell in your body can make all the cholesterol it
needs, it is not necessary to ingest any in your diet. However, there are other reasons (i.e.,
enjoyment) to occasionally eat a good steak.

Figure legend – Cholesterol is an essential component of cells that make up your body.
However, when it is too high, damage and blockage of your arteries occur. Most people in the
Western World have too much cholesterol in their blood, because of either unfortunate genetic
inheritance or poor lifestyle (or both). Genetic effects can be counteracted with medication and
lifestyle can be changed with a little effort. Do not let a high cholesterol level ruin your life!
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Chapter L3: Does the cholesterol in my food make a difference?
Clinical Vignette
Bill Springer is an obese 44 year old construction worker and lover of fast food. For lunch he
has two cheeseburgers, French fries, and a diet Coke (to lose weight). His coronary artery
calcium score is 465 with an LDL of 122 mg/dl and a CRP of 4.6. He read on the internet that
the cholesterol content of food does not affect the level of LDL in his blood. Bill would like to
know if there is any evidence that the cholesterol in his cheeseburgers increases his blood
LDL?
Comment
Bill raises an issue that is commonly stated on the internet that “cholesterol in food makes no
difference.” Before we answer Bill’s question, it is important to understand how Bill’s intestinal
tract handles cholesterol. Cholesterol in the intestine comes from two sources. Seventy-five
percent of it comes from the liver and 25% from the food that Bill eats. The liver secretes
cholesterol into the intestine to help digest fatty foods. This cholesterol mixes with Bill’s
cheeseburger cholesterol and then about half of this mixture is reabsorbed back into Bill’s
body. This cholesterol is then used by the intestine and the liver to package triglycerides for
the blood circulation. After the triglycerides are taken up by fat tissue and muscle, the
cholesterol remnant that is left is LDL.
How do we know that cholesterol in the diet will increase LDL cholesterol? There are several
lines of proof. First, volunteers have been fed diets containing different amounts of cholesterol.
As expected, the more cholesterol in the diet, the more the volunteers’ blood LDL increased.
Second, if 50% of the absorption of cholesterol in the gut is directly blocked with a drug (i.e.,
ezetimibe), circulating LDL levels decrease by 20%. Third, animals that eat plants normally
have very low LDLs unless fed a high cholesterol diet. There is a famous rabbit (the Watanabe
rabbit) that when fed a high fat and cholesterol diet actually develops plaques in its coronary
arteries. Finally, vegetarians who do not consume any cholesterol in their diet (vegans), have
very low LDL cholesterol levels. The average American diet contains 400 milligrams of
cholesterol.
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This is a huge amount considering that none at all is needed for healthy living. Some foods are
particularly high in cholesterol. For example, one egg yolk contains 170 mg of cholesterol.
The next time you are at the grocery store, be sure and read the label for the content of
cholesterol. You may be surprised at what you see. Small changes in your food choices can
make a big difference in your cholesterol intake. “Eating Smart” does not mean giving up foods
that you like. It means consuming foods that taste good and whose ingredients are good for
your health (i.e., low in cholesterol & saturated fat).

Figure legend – The food that you eat contributes 25% of the cholesterol that your body
absorbs from the intestine. This cholesterol is repackaged by the intestine and the liver. Some
of it ends up in circulating LDL particles. The LDL particles then enter the artery wall and
eventually form plaques in your arteries. Reducing cholesterol in your diet will reduce your
circulating LDL cholesterol and your chance for a heart attack.
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Chapter M1: What is the structure of LDL cholesterol?
Clinical Vignette
Carol Block is a 50 year old graphics art designer for an advertising firm. She constructs ads
for clients to help them sell their products. She believes that a “picture is worth a thousand
words”. She recently experienced chest pain while walking her dog up a long, steep hill. Her
physician ordered a calcium heart scan to assess her risk of a future heart attack. Her score
was 445 with most of the calcium in the anterior descending coronary heart artery (high risk
location). She has started a program of “eating smart” consisting of low saturated fat foods
and triple medication therapy to lower her LDL cholesterol and inflammation. Being an
inquisitive person, she would like to know “what does LDL cholesterol really look like?”
Comment
Carol asked a very good question. LDL cholesterol (abbreviated LDLc) is not just a drop of
grease that floats in your blood. It has definite and important structural characteristics. LDLc is
called a “remnant particle” because it remains after most all the triglycerides are removed. The
triglyceride is utilized by muscle and fat tissue for energy. The parts of the LDLc particle are:
1) The Beta protein (called apoB lipoprotein) - is a protein molecule made in the liver and
secreted into the blood with triglyceride. ApoB has a very important function. It binds LDLc
particles to the liver’s LDL receptors that remove LDLc from the blood. As you would predict,
people who cannot bind their LDL cholesterol to liver receptors have very high LDLc levels and
usually severe heart disease.
2) Phospholipids – These molecules naturally stick together and form spherical membranes
(similar to soap bubbles). Phospholipids have a unique property in that they are water soluble
on the outside but lipid (fat) soluble on the inside. This characteristic is important because they
can move around in the blood without forming a fat globule. However, like soap bubbles,
phospholipids are not very stable so cholesterol molecules are spaced randomly between them
to stabilize the membrane.
3) Cholesterol – this molecule comes in two forms. The simplest form is called unesterified
cholesterol - that means that nothing is attached to it. This form is located in the phospholipid
membrane for stabilization. Most of the cholesterol, however, locates itself on the inside of the
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LDLc particle. This form of cholesterol is called “esterified cholesterol” because it has an
additional molecule stuck to it (i.e., esterified to it). This attachment makes cholesterol more fat
soluble so it naturally moves into the center of the LDLc particle, away from the blood (blood is
mostly water). This part of the LDLc molecule eventually forms plaques in the heart arteries if
not removed by the liver first.
Like most things in life, too much of anything is as bad too little. You need a small amount of
LDLc to carry fat-soluble vitamins to your tissues, i.e., vitamins K, A, D, and E. People with no
LDL cholesterol suffer from vitamin deficiencies and people with too much LDLc suffer from
heart disease. If you keep your LDLc between 20 mg/dl and 50 mg/dl, you will have neither
heart disease nor vitamin deficiencies.

Figure legend – LDL particles have a definite structure that holds the particle together. The
numerous dark blue phospholipid molecules form the spherical membrane and are stabilized
by the orange non esterified cholesterol molecules. The yellow esterified cholesterol
molecules move into the center of the particle because they are fat soluble. The lighter blue
apoB lipoprotein molecule is critical for binding the LDLc particle to the LDL receptor on the
liver.
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Chapter M2: Are all LDL cholesterols created equal?
Clinical Vignette
Sam Brown is a 56 year old medically retired high school teacher who had a heart attack three
years ago. During his retirement, he has gained 30 pounds which he says is because he can
no longer exercise due to shortness of breath. He now leads a sedentary life watching TV and
playing cards with his friends. His wife recommends a cardiac rehab program and his doctor
agrees. His doctor warns Sam that his weight gain has increased his triglycerides and heart
risk by making his LDL into small, dense particles. Sam asks – “are not all LDL particles the
same?”
Comment
Before we answer Sam’s question, a little background on how LDL forms plaques may be
helpful. Low density lipoprotein (LDL) is a spherical particle that circulates in the blood and
gets deposited in the arteries as a cholesterol plaque. However, on its way from leaving the
blood and entering the arterial wall, two events must occur for it to form a plaque. First, it must
get through the lining of the inside of the artery (technically called the endothelium). To do this,
it must squeeze through a small opening between the cells lining the inside arterial wall.
Second, after it gets into the arterial wall, it combines with an oxygen molecule. It is then
engulfed by a macrophage (a white blood cell) and combines with other LDL particles to
eventually form a fatty streak, then a plaque.
LDL comes in two sizes, big and fluffy or small and dense. As you might guess, the big, fluffy
form has difficulty getting through the narrow spaces between the cells lining the inside of the
arteries whereas the small, dense LDL particles easily slip through. If this were not bad
enough, the small dense LDL particles very easily combine with oxygen molecules compared
to the big, fluffy ones. So, all LDL particles are not created equal.
Everyone can make both big, fluffy LDL and small dense LDL particles. So why do some
people make more of one kind than the other? It appears that the level of triglycerides that
circulate with the LDL in the blood are the determining factor. You can find out what your
triglyceride level is by looking at your lipid profile. The higher the triglyceride level, the more

128

small, dense LDL particles you make. A safe number for triglycerides is less than 150 mg/dl.
Above this level, you can be sure that you are making too many small LDL particles.
Another problem that you may have wondered about is the measurement of LDL. As you may
have deduced, an LDL cholesterol concentration does not tell you whether the LDL is big and
fluffy or small and dense. Therefore you could have an LDL concentration of 80 mg/dl and in
reality have a greater or lesser risk of heart disease than the LDL of 80 mg/dl would suggest
(depending on the size of the LDL particle). The total level of LDL of 80 mg/dl could either be a
few big LDL particles or many small LDL particles. You cannot tell which. This is one reason
that we highly recommend an LDL goal of 50 mg/dl. At this level of LDL, you are in a safe
zone no matter whether your LDL is big or small. If your triglycerides are high, reducing your
triglyceride level is also a good goal.

Figure legend – Small, dense LDL particles fit easily through the small spaces between the
inside lining of the artery wall. These particles rapidly combine with oxygen and eventually
form plaques. In contrast, large, fluffy LDL particles have difficulty getting through the lining
and also have difficulty combining with oxygen. Your triglyceride level will tell you what type of
LDL particles you predominantly make (if high triglycerides, then small LDLs).
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Chapter M3: What does PCSK9 have to do with my heart?
Clinical Vignette
Brad Schafer is a 35 year old insurance salesman who has a positive family history of heart
disease. His two brothers died of heart attacks in their late 30s and his father died of heart
failure at the age of 44 years. He has known that his LDL cholesterol (LDLc) was high since
being tested as a teenager. His doctor has treated him with a high potency statin plus
ezetimibe for the last six years and Brad has been following a low saturated fat diet since age
21. His most recent lipid profile demonstrated a very high LDLc of 189 mg/dl in spite of the
statin and diet therapy. His doctor suggested that he might be a candidate for PCSK9 antibody
therapy. Brad has no idea what his doctor is talking about.
Comment
PCSK9 antibody is the newest kid on the block for the treatment of hypercholesterolemia.
Since no one can pronounce the name of this chemical, everyone just abbreviates it by the
letters “PCSK9”. From Brad’s family history of heart disease and his high blood level of LDLc,
one can bet that Brad inherited his abnormal cholesterol gene from his father (as did his two
brothers). About one in every 200 people have the same genetic makeup as Brad.
Fortunately, there is a new treatment for Brad which will substantially lower his elevated
cholesterol. Two companies have recently received approval by the Food and Drug
Administration to sell an antibody based drug that inactivates PCSK9.
PCSK9 is a strange chemical that is secreted from the liver and then turns around and
prevents the liver from removing LDLc from the blood. It does this by destroying the liver’s
receptor for LDLc. This action results in very high LDLc levels. No one knows why this
happens. PCSK9 does not appear to serve any useful purpose in the body so removal of it by
the new antibody medication is very helpful in lowering LDLc. Some people are born with
practically no PCSK9 and they are healthy with very low LDL cholesterol levels. These new
antibody based drugs are taken once per month by injection and so far have very few side
effects. The antibody attaches to the PCSK9 molecule to block the molecule from acting. The
main drawback to their widespread use is their high cost (about $13,000 / year). Because of
this cost, insurance companies have restricted their use to people like Brad who have a genetic
cause of hypercholesterolemia.
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If you are interested in learning more about PCSK9 and the antibody drugs that block their
effects, there are several good short cartoon videos on the internet that show the drugs in
action. They provide more detail on just how these drugs work to protect the liver’s LDL
receptor from PCSK9. We recommend this video link
(https://www.youtube.com/watch?v=dOYgB7rAEAo) to our patients who may be candidates for
their use. Brad should discuss these drugs with his doctor and ask his doctor to talk to the
insurance company about authorizing its use. These drugs may save Brad’s life!

Figure legend -This drawing shows the liver’s LDL receptor (lavender) holding onto an LDLc
particle (light orange). The PCSK9 molecule (brown) is attaching itself to the LDL receptor and
eventually causes its destruction. Blocking the PCSK9 molecule with an antibody will save
LDL receptors and lower the blood LDL levels.
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Chapter M4: Why do I need LDL liver receptors?
Clinical Vignette
Betsy Crawford is a 39 year old high school teacher. When her father had a heart attack at
age 61, she wanted to know more about his disease. She found out that his LDL cholesterol
was elevated at 122 mg/dl in spite of a healthy diet. She read in one of her health magazines
that the key to longevity was to be born with extra liver LDLc receptors. “What does that have
to do with my father’s heart attack?” she asks.
Comment
We are pleased that Betsy asked this question and that her health magazine got it right. The
hepatic LDLc receptor is a protein that is made by the liver for one purpose – to remove LDLc
from the blood. The more LDL cholesterol receptors, the lower the circulating blood level of
LDLc. This fact was proved conclusively in a patient with no functioning liver LDL receptors.
This patient received a liver transplant and immediately reduced his circulating LDLc because
the LDL receptors on his new liver removed the LDL cholesterol. Dr. Brown and Dr. Goldstein
received the Nobel Prize for this discovery!
One way to have many LDLc receptors is to be born with them. You receive one gene for the
LDLc receptor from your mother and one from your father. The total sum of the activity of
these genes determines your starting receptor number level. Fortunately, there are additional
ways to increase the number of liver LDLc receptors. One approach is to eat a low cholesterol
diet. This diet depletes the liver of cholesterol, so it makes more LDL receptors to take up LDL
cholesterol from the blood. Another way to increase your LDLc receptors is to take cholesterollowering medications. For example, both ezetimibe and statins increase the number of LDL
liver receptors because they lower the level of cholesterol in the liver. As expected, the liver
responds by making more LDL receptors to take up more LDLc from the blood.
As is shown in the diagram below, the LDLc receptor sits on the liver’s surface waiting for an
LDLc particle to attach to it. When it does, both the LDLc particle and the LDL receptor move
into the liver cell. The LDL receptor then separates from the LDLc particle and this empty LDL
receptor is recycled back to the liver’s surface to attach to a new LDLc particle. It may surprise
you to learn that this LDL receptor recycling occurs every 10 minutes. Meanwhile, the LDLc
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particle is broken down into multiple parts. The cholesterol part is then made into bile acids
and secreted into the bile ducts of the liver. Bile acids help you digest the fats that you ingest
in your food.
To answer Betsy’s question, the more LDL receptors you have on your liver, the more removal
of LDLc from your blood will occur. This activity results in a lowering of your blood’s LDLc
concentration. The lower the LDLc concentration, the fewer heart attacks occur. Since heart
attacks are the number one cause of death in the United States, reducing circulating LDLc
results in a long lifespan for most people.

Figure legend -The liver’s surface is a busy place with many different receptors doing various
important functions. The LDL receptor lowers cholesterol by removing LDL particles. The
figure illustrates the LDL receptor removing LDL particles. The LDL receptor then moves back
to the liver’s surface to catch another LDL particle. The LDL particle is broken up, thereby
excreting cholesterol into the bile.
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Chapter N1: Are all cooking oils the same?
Clinical Vignette
Sarah Wingate is a 53 year old librarian who enjoys cooking meals for her husband Jack and
their adult son. Last month, her husband went for his annual medical checkup. His blood work
demonstrated an elevated LDL cholesterol, so his physician ordered a coronary artery calcium
scan. The result was a score of 877, indicating that Jack was at high risk for a heart attack.
The physician suggested that Sarah should “cook smart” by avoiding cooking with lard, bacon
grease, or butter (saturated fats). In their place, he suggested cooking and making salad
dressings with oils, but only “safe oils”. Sarah asks, “Are not all cooking oils the same?”
Comment
Sarah asks a very reasonable question. Sarah understands that cooking with animal fats (lard,
bacon fat, and butter) is not a healthy choice. Animal fats contain high levels of cholesterol
and saturated fat. However, oils derived from plants do not contain cholesterol because plants
do not have the metabolic machinery to make the cholesterol molecule. This fact does not
mean that plant-derived oils can’t raise the level of cholesterol in a person’s blood. Remember
that 75% of the cholesterol in the blood is made in the liver and 25% is derived from ingested
food. Therefore, the liver is an important source of cholesterol production.
The liver’s production of cholesterol is under the control of several factors including genetic
influences, medications, and various food ingredients. One of the most important food
ingredients is determined by the quantity of saturated fat it contains. Saturated fat is a
descriptive term for a fat molecule that has no double bonds between its carbon atoms. When
a fat molecule does have one or more double bonds, it is called “unsaturated.” There are two
types of unsaturated fat molecules, those with one double bond (call monounsaturated) and
those with more than one double bond (called polyunsaturated). It turns out, for reasons that
are unknown, that unsaturated fat molecules are beneficial and do not raise the liver’s
production of cholesterol. In contrast, saturated fats stimulate the liver to make cholesterol and
should be avoided.
As shown in the figure, fat oils tend to be different based on whether they are saturated or
unsaturated. The worst oil to consume is coconut oil, which contains 92% saturation. On the
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other hand, olive oil is 86% unsaturated and should be preferred in cooking and salad
dressings. Cooking with different oils induces different flavors in the food but chefs should try
to use as much unsaturated oil as possible. One reason that the Mediterranean Diet is famous
for its reduction in heart disease is that it is very high in the use of unsaturated oils, primarily
extra-virgin olive oil. We endorse this approach to cooking smart. Sarah can help her husband
reverse his heart disease by preparing foods using unsaturated oils.

Figure legend – As the computer screen shows, there are many different oils with which to
prepare foods. Oils containing a high concentration of saturated fat (shown in orange) should
be avoided, as they increase the circulating concentration of LDL cholesterol. In contrast, olive
oil is low in saturated fat but high in unsaturated fat and is therefore a good choice, as it is
widely available at a modest cost.
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Chapter N2: Can I lower my LDL cholesterol with natural foods?
Clinical Vignette
Roy Jackson is a 42 year old rancher who raises Black Angus beef for market. In the evening,
he loves to surf the internet to keep up with current events. He has an unfortunate family
history of heart disease with his father dying at age 46 years of a heart attack. From the
internet Roy learned that a coronary artery calcium scan was an excellent test to check on the
health of his heart. To his credit, he had his physician order this test and Roy’s score was 866,
putting him at high risk. His lipid profile revealed that his LDL cholesterol was 123 mg/dl. His
physician recommended that he take 10 mg of rosuvastatin and 10 mg of ezetimibe. Not a
believer in pills, he asked “Can I take natural foods to lower my cholesterol instead of pills?”
Comment
Roy has learned from the internet that many foods and herbs lower cholesterol. He is correct.
Many individuals would like to take this approach before starting any medications to lower their
LDL cholesterol. We encourage this approach. We always recommend that they get a
baseline lipid profile before starting natural foods and herbs so the patient knows his/her
starting LDL cholesterol level. After three months, which will give their new diet a chance to
lower their LDL cholesterol, they should repeat their lipid profile to see what they have
achieved. Roy needs to remember that the goal to reverse his proven heart disease and
reduce his high risk is an LDL cholesterol below 50 mg/dl.
The list of foods and herbs that are touted as lowering cholesterol are too extensive to be
covered in this chapter. However, they all work through a limited number of pathways. Most
obvious are foods that contain much fiber (mostly vegetables) which bind cholesterol in the gut
and prevent its intestinal absorption. Other foods contain statin-like compounds that decrease
the production of cholesterol by the liver (e.g., red yeast rice). Other foods (such as walnuts)
are high in polyunsaturated fatty acids which have LDL lowering activity by pathways not well
understood. Obviously, people choose different foods depending upon their individual
preferences.
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What the advocates of eating foods and herbs to lower LDL cholesterol do not tell you is how
much (i.e., by what percentage) the foods they recommend will lower the cholesterol level. At
most, this reduction is usually 10 to 20% of the original starting level. Since Roy is starting at
an LDL cholesterol level of 123 mg/dl, at best his level after changing his diet will be
approximately 100 mg/dl. This level of LDL cholesterol will not prevent Roy from having a
heart attack. In fact, Roy will continue making plaques in his coronary arteries until he suffers
a serious cardiac event. It is a foregone conclusion that Roy will eventually have to take
medications to reach his LDL goal of less than 50 mg/dl.

Figure legend – the internet has much information on foods and herbs that lower cholesterol.
Taken in reasonable amounts, these foodstuffs do not cause harm. However, rarely, if ever,
will they be potent enough to allow an individual to reach the LDL cholesterol goal of <50
mg/dl. We encourage our patients to try whatever foods that they think are beneficial to lower
cholesterol but not to delay more than a month in considering medication to reverse their
atherosclerosis.
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Chapter N3: Is exercise good for me and my heart?
Clinical Vignette
Josephine LeBlanc is a 48 year old woman who has a full time sedentary job at a government
office. She is obese with prediabetes and hypertension which she blames on her stressful
sedentary job. When she gets home in the evening, she fixes dinner for her family and then
relaxes watching her favorite TV shows. She says that she occasionally snacks because “she
gets hungry”. She further says “people tell me to exercise but I tried that for three months and I
did not lose a pound. What is the point?”
Comment
The point to be made for Josephine is that exercise has several beneficial effects to prevent
cardiovascular disease. It is not a panacea for obesity. Numerous studies comparing
sedentary people with people who exercise demonstrate a prolongation of life in the exercising
group. However, whether it’s the exercise itself or the lifestyle adopted by exercising people is
not known. Compared to the comparative control group, exercising people are thinner, eat less
red meats, consume more vegetables and fruits, and have fewer cardiovascular risk factors.
The beneficial metabolic changes that are caused by exercise include a person’s increase in
the sensitivity to circulating insulin resulting in an improvement in diabetes and prediabetes.
Exercise also results in an elevation of HDL cholesterol which may reduce coronary events.
Inflammation is also reduced resulting in a reduction of C-reactive protein.
However, exercise does not automatically result in weight loss. One problem with exercise is
that it tends to lower blood sugar since muscles use glucose for energy. Lower glucose can
increase appetite resulting in an increase in additional food intake. This then cancels the
potential weight loss from the calories consumed during exercise. This is probably what
happened to Josephine during the three months of her “exercise trial”.
Exercise is often divided into aerobic and anaerobic activities. Aerobic exercise can be
defined as brisk exercise that promotes the circulation of oxygen through the blood and is
associated with an increased breathing and heart rate. Typical examples include jogging,
swimming, and bicycling. However, anaerobic exercise also burns calories and walking is a
good example. In the adult population, the type of exercise is often limited by medical
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conditions that only permit certain activities that burn calories; walking is a good example. The
important point is that everyone can do some type of exercise and staying active is vitally
important for maintaining good health. Josephine needs to make a determined lifestyle change
and include exercise in her daily routine. Studies have shown that a minimum of 30 minutes of
exercise at least three time per week will result in important, beneficial health changes that
reduce your cardiovascular risk factors.

Figure legend – There are many types of exercise that are beneficial to your health. The
important point is to choose one that you can do and to do it on a regular basis. It is part of
making a lifestyle change and a commitment to reducing your risk factors for heart disease.
Inexpensive pedometers are a good way to track your daily walking steps. Other devices,
including “apps” on cell phones may also help.
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Fall cottonwood trees in full color. New Mexico has one of
the largest cottonwood forests along the Rio Grande bosque.
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Elephant Butte Reservoir in central New Mexico. Note the old TB Hospital
on the right-middle of the photo which is usually submerged
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Chapter O1: Why are dietary fats important to you?
Clinical Vignette
Sam Lemont is a 40 year old salesman in an outdoor equipment store. He is healthy and fit,
working out at the gym three times per week. Unfortunately, he has a very strong family
history of heart disease with his father and two brothers dying of heart attacks in their fifties.
He would like to gain some more muscle mass in his arms and thighs to help his hiking
stamina and outdoor activities. However, he doesn’t seem to be able to gain weight, no matter
how much he eats. His wife insists he eat a very low fat diet because she says, “Fat is bad for
your heart.” He wants to know “Is it true that fat will kill me?”
Comment
As with most things in life, fat is both good and bad; thus, “Not all fats are created equal.” First,
the good news. It was recognized 40 years ago that some fats in the diet are essential for
good health. The body can synthesize most of the fats it needs for metabolism. However, two
essential fatty acids, linoleic and alpha-linolenic, cannot be made in the body and must be
obtained from food. These basic fats, found in plant foods, are used to build specialized fats
called omega-3 and omega-6 fatty acids. In addition, most of the energy that our body needs
every day comes from the fats called triglycerides. Fat is a very concentrated form of energy.
It is the reason that you put gasoline (a fat) in your car and not wood chips (a carbohydrate).
We all need some fat in our diet to build up our energy stores in case we become sick or
engage in exercise.
Now for the bad news. Some fats serve no useful purpose and in fact, can be harmful to your
heart. As detailed in another chapter cholesterol (a fat) can cause heart disease and gall
stones. Since every cell in the body can make as much cholesterol as it needs, there is no
beneficial purpose of consuming cholesterol after adulthood has been reached. This “bad”
cholesterol is transported in your blood by low density lipoprotein particles (LDL cholesterol). It
is left over (a remnant) after triglycerides are used for energy by your muscles. It is increased
by the amount of saturated fat and cholesterol you eat from animal food sources. It is normally
removed from the circulation by your liver. However, when the amount gets too high in your
blood, it spills over and gets deposited in your heart arteries. Over time, it forms plaques in
your arteries and causes a heart attack.
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Returning to Sam’s problem of not being able to gain weight, he should increase good fats
(most oils) and avoid the bad fats (butter, margarine, and lard) in his diet. That way, his
muscles will have sufficient energy to be at their maximum performance and Sam will gain
some much needed muscle mass.

Figure legend – It is important to choose the right fat in your diet for cooking, salad dressing,
and adding flavor to foods. There are many healthy oils to choose from which are heart
healthy. Take your time to read the label and avoid foods that contain cholesterol, saturated,
and trans fats.
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Chapter O2: Should I take plant sterols to lower my cholesterol?
Clinical Vignette
Charlotte Weber is a 39 year old dietician who is determined to improve her health through
eating smart. She has read extensively on foods that lower cholesterol and is convinced that
taking one of the products at the health food store will reduce her LDL cholesterol (which is 123
mg/dl) to less than 50 mg/dl. She was motivated to improve her lifestyle when her coronary
calcium score was reported as 122. Her only risk factor is type 2 diabetes which she blames
on bad genes because both of her parents also had diabetes. She wants to know if taking the
plant sterols will interfere with the 10 mg/day of rosuvastatin that her doctor prescribed.
Comment
Health food store products are very popular in the United States, and people spend billions of
dollars per year buying them. Because these products are not under the regulation of the Food
and Drug Administration, very few studies are available to prove or disprove the claims that
health food product manufactures claim. Therefore, we cannot answer Charlotte’s question
directly with scientific studies, but we can address it indirectly by examining how plant sterols
work.
Plants cannot make cholesterol, but they can make other molecules that look like cholesterol
(called plant sterols). Plants use these molecules to build cell walls and stabilize other parts of
their cells. When you eat plant foods (vegetables, fruits, etc.), you ingest plant sterols that mix
with cholesterol molecules that you ingest when you eat animal foods (meat and dairy
products). Recently discovered is a specific receptor on the surface of your intestinal cells that
recognizes cholesterol and absorbs it into the body. Plant sterols fool this receptor into
thinking that they are cholesterol and the receptor absorbs them also. However, another
receptor in the same cell is not fooled by plant sterols and kicks them all back out into the
intestinal lumen for excretion in the stool.
If the intestinal cholesterol receptor becomes overwhelmed with absorbing plant sterols, the
end result is the absorption of very little cholesterol.
This in turn results in lowering the circulating cholesterol (LDL) by approximately 10 to 15%.
Since statins work at the liver (and not at the intestine) to lower cholesterol synthesis, plant
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sterols do not interfere with the beneficial effects of statins. In fact, the two approaches to
lowering cholesterol work very well together to let Charlotte achieve her LDL goal of 50 mg/dl.
The medication ezetimibe works in a similar way to plant sterols by blocking the intestinal
cholesterol receptor. However, ezetimibe is more effective and reduces LDL cholesterol by
approximately 20%.

Figure legend – Plant sterols provide a natural way to lower your LDL cholesterol level. They
confuse the intestinal cholesterol receptor and as a result, much less cholesterol is absorbed
into the body. A diet high in fruits and vegetables will provide a large amount of plant sterols
and is one component of the “heart protecting” Mediterranean diet. Plants foods are also a
good source of fiber, which binds cholesterol and prevents its absorption. People respond
differently to diet and medications. Therefore, you should always confirm your benefit by a
laboratory measurement of your LDL cholesterol to be sure you are reaching the goal of <50
mg/dl.
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Entrance to Monticello Canyon in New Mexico. The creek that
carved the canyon was carved by Geronimo Hot Springs.

153

154
Malpais (bad lands) – 10,00 year old lava flow.
Valley of Fires, Carrizoz New Mexico

P
Alternative
Approaches
to Preventing
Heart disease
155

Chapter P1: What has age got to do with it?
Clinical Vignette
Sam Martin is a 70 year old retired carpenter who used to smoke a pack of cigarettes a day
until he realized how dangerous they are. He recently spoke to his 36 year old son, Patrick,
who has had type 1 diabetes since the age of thirteen. Both are healthy for their respective
ages, but each is concerned about the possibility of developing heart disease. Their family
doctor (who treats both father and son) is not concerned about heart disease, for the father
because he is too old and the son because he is too young to worry about it. The Martins want
to know, “What has age got to do with it?”
Comment
Sam and Patrick Martin are correct. It is never too early or too late to ask about the condition of
your heart. People can die at any age from a heart attack. In fact, when the genetic disease
called homozygous familial hypercholesterolemia (a horrible long, unpronounceable name)
afflicts a person at birth, that person may have a heart attack before he/she ever reaches the
teenage years. Screening for this or similar genetic conditions is now recommended at an
early age because medical treatment is life-saving.
What is defined as old age is arbitrarily chosen by individual preference. Two centuries ago,
old age was anyone over the age of 50 because the average lifespan was 45 years. At the
present time, with the average expected lifespan is in the 70’s. Many people living productive
lives, live into their 80’s and 90’s. Old age has become a nebulous term. In addition, it is
important to distinguish between chronological age and biological age. Chronological age is
the number of years that a person has lived. Biological age is the current state of health of the
individual and his/her expected life expectancy. For physicians who must recommend
treatment goals, the biological age is the more important.
So should Sam’s physician assess the health of Sam’s heart and recommend treatment if
abnormalities are found? There are no hard and fast rules. Our approach is simple. If an
individual’s biological health indicates that he/she will not live another five years, than treating
potential heart disease will not necessarily yield a long-term beneficial result. On the other
hand, if the person’s expected lifespan is greater than five years, and a heart attack would be
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detrimental to the remaining active years of the individual, than we recommend preventative
treatment. We do not consider the chronological age of the individual in helping us decide if
treatment is warranted.
What about Sam’s son Patrick? Currently, few physicians aggressively diagnose and treat
heart disease in individuals less than 40 years of age. We think this is a mistake. Thousands
of individuals die of heart disease in their forties, and prevention requires several years to
stabilize and reverse atherosclerotic plaques. Diagnosing heart disease in the third decade of
life provides sufficient time to reverse the disease before a coronary blockage causes a heart
attack. When a young individual has significant risk factors for heart disease (such as
diabetes), performing a coronary artery calcium scan before age 40 makes very good sense.
Patrick should have this test plus some other blood tests (lipid profile and hsCRP) to assess
his risk and exclude any heart disease present. We recommend that both Sam and Patrick
discuss this option with their family doctor and request the appropriate evaluation of their
hearts, including a coronary artery calcium scan and appropriate blood tests.

Figure legend – Age should not be used to exclude obtaining a coronary artery calcium heart
scan.

If an individual is relatively healthy and enjoying life, identification and prevention of

heart disease is an important obligation for all physicians.
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Chapter P2: Do I need Cardiac Rehabilitation?
Clinical Vignette
Alex Sanders is a 65 year old retired school administrator. He smoked for most of his life, has
high blood pressure, and type 2 diabetes. His brother recently died of a heart attack on the
golf course. Last month he had a heart calcium scan which greatly concerned him. His score
was 1,145 with calcium in every heart vessel. His physician started him on medications to
lower his LDL cholesterol and recommended a low saturated fat diet. However, Alex wants to
do everything he can do to reduce his heart attack risk. His physician recommends that he join
a cardiac rehabilitation program. “What is that?” he asks. “I thought those programs were only
for people who have had a heart attack.”
Comment
Cardiac rehab programs are for anyone who has an increased risk for heart disease, whether
or not they have had a heart attack. A positive cardiac calcium scan qualifies a person for
these programs. They are available in all major towns and cities. Studies have demonstrated
that there are real benefits to joining these programs, including greater exercise tolerance,
more energy, improved glucose control, weight loss, and a longer life span. Most programs
consist of attendance three times weekly, electrocardiogram monitoring if necessary, and hourlong exercise sessions for 8 to 10 weeks. The goal of these sessions is to teach participants
an individualized exercise program. It is important that the prescribed protocol be both safe
and effective at improving cardiovascular health, that it will reduce coronary heart risk factors,
and that it will address any psychosocial issues that may be present from knowing that the
individual has heart disease.
Medical insurance companies often cover the cost of these programs, as well as the cost of
medications to treat the hypertension, diabetes, and abnormal lipid profiles. For individuals
who have not already have had a heart attack, cardiac rehab programs are very safe with the
result of improved health. They are an excellent way of making a commitment to improve your
health and assure your family that you are committed to a long life. We strongly recommend
that Alex join one of the cardiac rehab programs in his town.
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One advantage of cardiac rehab programs is meeting other people who also have a high risk of
having a heart attack. Individuals who have had one heart attack are at very high risk of
another heart attack. They have learned that prevention is the key to good health. Each will
have a story to tell and a lesson to be learned. We guarantee you that you will enjoy your
rehab sessions and so will your heart. This is a great way to get started with changing your
lifestyle for the better. What have you got to lose?

Figure legend – Cardiac rehab programs benefit everyone. You do not need to have had a
heart attack to reduce your risk. The rehab program that you choose will develop a program
tailored to your needs and available time. These programs are widely available and are very
modestly priced. Multifactorial rehabilitation programs consist of a baseline assessment,
nutritional counseling and weight management, aggressive coronary artery risk factor
management, psychosocial assessment, physical activity counseling, and exercise training.
They are a great way to get your heart attack risks under control.
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Chapter P3: To Stent or Not to Stent?
Clinical Vignette
Fred Grey is a 55 year old bus driver who leads a sedentary lifestyle. He smoked cigarettes for
21 years but quit 3 years ago when his physician warned him of smoking’s dangers. He is
overweight with a BMI of 29. Although he has a history of diabetes in his immediate family, he
currently only has prediabetes for which his physician prescribed metformin. Someone told
him that his cholesterol was “OK” but he does not know the number. In the last two months, he
has been experiencing shortness of breath and chest “tightness’ when he walks up two flights
of stairs to his apartment but at no other time (called “stable angina”). His physician ordered a
heart stress test, which was “positive”. His physician now wants to refer him to a cardiologist
for coronary angiography. If a heart artery constriction is seen, a “stent” will be placed in his
heart artery to “open it up”. He was also told that this procedure could cost up to $40,000,
which his health insurance only partially covers. Fred wants to know if there is a less
expensive alternative.
Comment
We are pleased to tell Fred that there is a better alternative than placing a stent in his heart
artery. A cardiac “stent” involves threading a catheter up into one of the heart’s arteries to the
atherosclerotic plaque causing the narrowing (which has previously been identified with a
coronary angiogram). A wire mesh is then placed in the narrowed segment of the artery and
expanded with an inside balloon tipped catheter, thereby enlarging the artery (see figure).
Recent medical studies have clearly demonstrated that intensive medical therapy is the
treatment of choice for Fred’s stable angina (i.e., chest pain occurring only when exercising).
One study compared stents with medical therapy in patients who were not aware of which
treatment they received. At the end of 2 months, all patients equally improved irrespective of
the choice of treatment. Another study compared medical therapy with or medical therapy
without stent placement. At the end of three years, the stent made no difference in the
patients’ quality of life. All patients improved to the same extent as a result of the medical
therapy.
There are three drawbacks with stents placed is cardiac blood vessels. First, they are
expensive as illustrated by Fred’s case. Second, they do not prevent future heart attacks since
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they are only enlarging one small part of an artery that likely has plaques throughout its length.
Third, they do not result in an improved outcome for the patient, either in the short term or in
the long term. Fourth, they are invasive with a small but real chance for medical complications.
The reason that medical therapy is as good as a heart artery stent is that a partially blocked
heart artery undergoes “remodeling” with new blood channels developing which bypass the
partial heart obstruction. In addition, medical therapy, which involves LDL cholesterol lowering
medication and lifestyle changes, will result in reversing the heart artery atherosclerotic plaque.
To accomplish this positive outcome, the patient lowers his/her LDL cholesterol below 50 mg/dl
with a low saturated fat diet and the addition of ezetimibe and rosuvastatin.

Figure legend – A wire mesh stent is placed in a heart artery at a location narrowed by
atherosclerotic plaque. A balloon inside the stent expands, enlarging the stent and the
narrowed artery. The balloon is removed leaving the stent in place in the enlarged artery. The
plaque is squeezed against the artery wall with minimal consequences .Some patients receive
multiple stents because most arteries have numerous places where the artery is narrowed.
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Sunset over the desert with Sandia Mountains in
background near Albuquerque, NM

Contributed by: J. Padilla
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Q1: The Nuts and Bolts of a Heart Attack
Contrary to popular belief, a heart attack doesn’t just
happen. In fact, it silently threatens for many years before
the catastrophic event occurs. Knowing how it occurs is the
key to prevention. The figures and text below will provide
you the “nuts and bolts” of how it happens so you can
prevent one.
When you were born, your arteries were clean,
smooth pipes, through which your blood flowed
unobstructed to reach your vital organs, i.e., the brain,
heart, lungs, and kidneys.
In this blood are red blood cells to carry oxygen, white
blood cells to fight infection and remove foreign
particles, and platelets to stop any bleeding in case
you cut yourself. Then as you started to consume
food (e.g., dairy products of milk, eggs, cheese, etc.), your body needed a safe way to move
the fat in these foods through your blood to your muscle to be used as energy. It could not
simply secrete fat into your blood because fat is not soluble in blood (think of adding drops of
oil to a cup of water). Therefore, your body developed a way of packaging the fat in your
blood. Soluble fat particles consisting of protein and cholesterol surrounding the fat globule
worked well. This turned out to be an excellent
solution, and your muscles (including your heart)
received all the fat energy they needed.
The problem then arose as to what to do with
the leftover protein and cholesterol after the fat
was used for energy. Unfortunately, your body
has no way of breaking down the cholesterol, so
your body developed an ingenious solution. It
constructed specific cholesterol removers (called LDL receptors) on the liver which take up the
cholesterol and excrete it into the intestine for ultimate elimination in the stool.
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This approach worked very well until you consumed too
much fat and the liver’s LDL receptors were
overwhelmed with cholesterol removal. The remaining
excess cholesterol then moved passively into the walls
of the arteries and formed atherosclerotic plaques that
result in heart attacks.
The leftover particles of cholesterol and protein are
called lipoproteins (lipo = lipid = fat). The specific
lipoprotein left over when the fat is removed is called “low density lipoprotein” because it is not
very heavy when spun in a centrifuge. This is
the specific particle that is taken up by the
liver’s LDL cholesterol receptors (LDL
cholesterol particles = LDLc for short). These
particles circulate in the blood, waiting to be
taken up by the liver or to move into the wall of
your arteries. Whether they do the former or
the latter activity is dependent on several
conditions in the artery. The primary barrier to
movement of LDLc particles into the walls of the artery is the thin, one cell thick, inside lining of
the artery called the “endothelium” (shown in the first figure above). If this endothelium lining is
healthy, very few LDLc
particles get through. But
if it gets damaged by an
“insult”, such as smoking,
hypertension, or diabetes,
then the LDL particle
easily gets through.
Once through the endothelium, the LDL particle needs to join with other LDL particles to form a
plaque. This is where the white blood cell called the “macrophage” (big eater) comes in.
Normally, there are very few macrophages in the artery wall. However, when the endothelium
is damaged, macrophages easily get through the endothelium and can engulf the LDL particles
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in the artery wall. Unfortunately, the macrophage cannot digest the LDLc particle, so it
becomes engorged with cholesterol and dies. When several macrophages die in close
proximity, they form a fatty streak. This streak becomes the beginning of an atherosclerotic
plaque. As the fatty streak matures, it collects
many other substances, including calcium, smooth
muscles cells, and molecules called proteinases.
These proteinases collect on the side of the
atherosclerotic plaque and eventually dissolve the
cap covering the plaque. In other words, the
plaque ruptures into the lumen of the artery (the
opening in the artery through which the blood
flows). This rupture is detected by platelets
circulating in the blood that is flowing through the
artery. The platelets act as small plugs in an attempt to repair the rupture. They also activate
a blood clot to further plug the rupture. Unfortunately, this blood clot may become large
enough to totally obstruct the artery. If the
artery is in the heart, a heart attack results.
Preventing a heart attack is not rocket science.
It involves protecting the endothelium, lowering
the LDLc to levels that the liver can safely
remove, and limiting the number of
macrophages that can move into the artery
wall. This book will explain how to achieve all
three of these goals. It may well save your life!

The good news is that you also have a method
to remove the plaque once it has formed called “HDL cholesterol”. It carries LDL-derived
cholesterol from the plaque in the wall of the artery to the liver for disposal. But it too can be
overwhelmed if you don’t limit your food cholesterol ingestion. That is why we say “Eat smart
and live long.”
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Q2: Interview with the Author

Dr. Barry Ramo (below, left), a well-known cardiologist and television
commentator, periodically holds interviews with physicians in Albuquerque
on topics of interest to the public. One topic that he moderated was
Preventing and Reversing Heart Disease with Dr. David S. Schade, who
presented the current thinking on preventing the number 1 cause of death
in the United States. This presentation and subsequent interview is shown
in this video.

Instructions: Go to Youtube.com, type in City of Albuquerque GOVTV,
Search Dr. Schade or type the link below into your computer browser:
https://www.youtube.com/watch?v=MXQtNxrp0ZE&feature=youtube
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Number Zero

Q3: <50 Achievement Club
Join the winners – who have achieved an LDL cholesterol level of less
than 50 mg/dl for at least one year. Receive a certificate of achievement,
a <50 lapel pin, and a “50 Ways to Save Your Heart” Book”.
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R1. Index & Dictionary
Aspirin (used to relieve mild pain, reduce fever, and inflammation): 10, 20, 47, 56, 60, 61, 69,
84, 96, 97, 100, 101, 102, 103 - See Chapter J2, p. 96.
Atherosclerosis (a disease in which plaque builds up inside your arteries): 6, 7, 8, 9, 16, 19,
46, 47, 49, 56, 58, 59, 64, 68, 77, 101, 102, 108, 141 – See Chapter A1, p. 6.
Angina (chest pain caused when your heart doesn't get enough oxygen-rich blood): 6, 7, 38,
160 - See Chapter A2, p. 9.
Blood Clot (a gelatinous or semisolid mass of coagulated blood): 9, 26, 96, 97, 168 – See
Heart Attack p. VI
Blood Pressure (the pressure of the blood in the body): 8, 36, 48, 66, 72, 73, 76/77, 82, 158 See Chapter H1, p. 72.
Brown and Goldstein (Nobel Prize Winners for research in cholesterol metabolism): 6, 132 See Chapter M4, p. 132.
Calcium Scan (provides pictures of the heart to measure calcium-containing plaque in the
arteries): 8, 10, 16, 24, 25, 29, 36, 48, 82, 100, 102, 103, 108, 109, 113, 119, 138, 140, 157,
158- See Chapter C2, p. 26.
Cholesterol (white substance that collects on the walls of arteries and interferes with the flow
of blood): 6, 8, 9, 10, 18, 19, 20, 21, 26, 40, 46, 47, 48, 50, 56, 60, 61, 64, 65, 68, 69, 72, 86,
94, 95, 96, 98, 99, 100, 102, 110, 118, 119, 120, 121, 122, 123, 126, 127, 128, 130, 132, 133,
138, 140, 141, 148, 150, 151, 166, 167, 168 – See Heart Attack p. VI
Cholesterol Plaque (A semi-hardened accumulation of substances from fluids): 7, 8, 9, 10, 11,
20, 24, 26, 40, 46, 48, 96, 97, 102, 103, 118, 119, 128, 161, 167, 168 – See Heart Attack p. VI
Coronary (the arteries that surround the heart): 8, 24, 25, 27, 46, 48, 67, 72, 96, 102, 103,
108, 109, 119, 122, 157 - See Chapter C1, p. 24.
Coronary Artery (artery supplying blood to the heart): 24, 25, 48, 72, 96, 102, 103, 108, 109,
119, 157 - See Chapter C1, p. 24.
CT Scan (X-ray image made using computer images): 24, 29 - See Chapter C1, p. 24.
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Diabetes (body’s ability to produce or respond to insulin is impaired): 20, 40, 48, 72, 82, 84,
87, 100, 142, 150, 158, 160 - See Chapter H1, p. 72.
Diet (restrictions on what one eats): 17, 18, 20, 21, 46, 60, 68, 120, 121, 122, 123, 130, 132,
139, 140, 141, 148, 149, 151, 158, 161 - See Chapter O1, p. 148.
Exercise (engage in physical activity): 8, 18, 26, 38, 40, 56, 64, 76, 100, 119, 120, 128, 142,
143, 148, 158 ,159 - See Chapter N3, p. 142.
Ezetimibe (a drug that lowers plasma cholesterol levels): 10, 17, 20, 21, 47, 56, 59, 60, 66, 69,
76, 77, 82, 83, 84, 86, 87, 94, 95, 96, 97, 98, 99, 100, 101, 102, 122, 130, 132, 140, 151, 161 See Chapter J1, p. 94.
Framingham (town in Massachusetts where studies of heart disease occur): 6, 74, 75 - See
Chapter H2, p. 74.
Gene (heredity unit): 8, 11, 18, 19, 58, 75, 94, 121, 132, 138, 150, 156 - See Ch B2, p. 18.
HDL (combinations of fats and proteins transported in the blood): 64, 65, 95, 118, 119, 142,
168 - See Chapter L1, p. 118.
HDL Cholesterol (cholesterol present in the blood as high-density lipoprotein): 64, 65, 95, 118,
142, 168 -- See Chapter L1, p. 118.
Heart Attack (damage to an area of heart muscle that is deprived of oxygen): 6, 7, 8, 9, 10, 17,
18, 20, 26, 40, 48, 50, 56, 57, 58, 59, 68, 75, 82, 84, 85, 86, 87, 96, 102, 103, 108, 118, 119,
120, 132, 133, 148, 156, 158, 159, 166, 168 - See Chapter A2, p. 6.
Heart Failure (failure of the heart to pump blood with normal efficiency): 59, 86, 110, 130 - See
Chapter F1, p. 56.
hsCRP (abbreviation for High Sensitivity C Reactive Protein. The High Sensitivity refers only
to the specific assay used to measure the CRP. CRP is a measure of inflammation. The safe
goal is <1.0 mg/L.): 9, 10, 11, 16, 47, 48, 50, 56, 57, 60, 61, 66, 72, 77, 96, 100, 101, 102, 112,
113, 118, 119, 157 - See Chapter A3, p. 10.
Hypertension (abnormally high blood pressure): 6, 10, 16, 20, 24, 25, 40, 46, 48, 56, 68, 72,
74, 75, 77, 82, 101, 108, 110, 142, 158, 167 - See Chapter H2, p. 74.
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Inflammation (part of the body that is reddened, swollen, and often painful): 6, 7, 9, 10, 11, 16,
20, 36, 47, 48, 56, 60, 61, 66, 69, 72, 96, 100, 102, 118, 126, 142 - See Chapter A3, p. 10.
LDL (low density lipoprotein): 8, 9, 10, 16, 20, 21, 46, 47, 48, 50, 56, 60, 61, 64, 66, 68, 69, 72,
82, 86, 95, 96, 98, 100, 102, 118, 119, 122, 123, 126, 127, 128, 129, 130, 131, 132, 133, 140,
141, 150, 151, 161 ,167 - See Chapter M1, p.126.
LDL Cholesterol (‘bad’ cholesterol): 8, 9, 10, 20, 21, 46, 47, 48, 50, 56, 60, 61, 64, 68, 69, 72,
86, 95, 96, 98, 100, 122, 126, 130, 132, 140, 141, 151, 161, 167- See Chapter M1, p.126.
Lipid (fatty acids like natural oils, waxes, and steroids): 16, 18, 19, 21, 36, 64, 65, 112, 113,
126, 127, 128, 130, 140, 157, 158, 167 - See Chapter G1, p. 64.
Lipid Profile (group of tests measures the amount of cholesterol and other fats in one’s blood):
16, 18, 19, 21, 36, 64, 65, 112, 113, 128, 130, 140, 157, 158- See Chapter G1, p. 64.
Liver (organ in the abdomen): 6, 47, 60, 64, 86, 95, 98, 99, 118, 120, 122, 123, 126, 127, 130,
131, 132, 133, 138, 140, 148, 150, 166, 167, 168 - See Chapter M4, p. 132.
Macrophage (a large cell found at sites of infection): 9, 10, 96, 128, 167, 168 – See Heart
Attack p. VI
Nobel Prize (a prize awarded for outstanding work): 6, 18, 132 - See Chapter M4, p. 132.
Platelet (a component of blood whose function (along with the coagulation factors) 96, 97, 166,
168 – See Heart Attack p. VI
Receptor (a cell or organ able to transmit a signal to a sensory nerve): 47, 94, 95, 98, 126,
127, 130, 131, 132, 133, 150, 151, 166, 167 - See Chapter M4, p. 132.
Rosuvastatin (a member of the drug class of statins): 17, 20, 21, 47, 56, 59, 60, 66, 69, 82,
83, 84, 85, 87, 94, 96, 97, 98, 99, 100, 101, 102, 140, 150, 161 - See Chapter J4, p. 100.
Risk (exposure to danger or harm): 8, 9, 10, 16, 17, 20, 25, 26, 40, 46, 48, 49, 50, 51, 56, 57,
60, 68, 72, 73, 74, 75, 76, 77, 84, 85, 87, 97, 100, 108, 109, 119, 126, 140, 142, 143, 157,158,
159 - See Chapter H1, p. 72.
Stress Test (a test of cardiovascular capacity): 38, 39, 160 - See Chapter D2, p. 38.
Stent (tube to open blocked blood vessel): 56, 58, 96, 160, 161 - See Chapter P3, p. 160.
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Stroke (an interruption in the flow of blood to the brain): 7, 10, 16, 17, 19, 86, 96, 108, 120 See Chapter A2, p. 8.
Triglycerides (a type of fat): 65, 95, 122, 126, 128, 129, 148 - See Chapter G1, p. 64.
Triple Therapy (a combination of three medications, rosuvastatin, ezetimibe and aspirin, to
treat heart disease): 20, 60, 61, 84, 97, 100, 101, 102, 108 - See Chapter J4, p. 100.
White Blood Cell (cell circuling in the blood): 10, 96, 128, 166, 167 – See Heart Attack p. VI
Zetia (brand name for ezetimibe): 94 - See Chapter J1, p. 94.
Bold numbers indicate the word was mentioned more than 5 times on that page.

The VLA (very large array) is a world class radio telescope on the
Plains of St. Augustine near Socorro, New Mexico. It is studying the
black hole at the center of our galaxy.
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Albuquerque, New Mexico in the winter. The 10,500 foot Sandia mountain includes a
ski slope, a tram to the top, and multiple hiking trails.
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Carlsbad Caverns in southeast New Mexico housing
enormous colonies of Mexican free-tailed bats.

Billy the Kid, born in 1859, also known as William H. Bonney, was an outlaw
and gunfighter who killed eight men before he was shot and killed at age 21
by Sheriff Pat Garrett. He took part in New Mexico's Lincoln County War,
during which he allegedly took part in three murders.
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An Opportunity for you to Save a Life!

Have you enjoyed reading this book? Do you want other folks to enjoy it?
As you know, we never charge money for this book. We have no sponsors. The
book is downloadable at no charge on the internet. However, a downloaded
version is never as good as reading a real hard copy. You can make this
possible.
Make a tax deductible donation of $50 to “50 ways to save your heart” to the
University of New Mexico Foundation at, 700 Lomas Blvd NE, Albuquerque, NM,
87102. This donation will purchase two books to be distributed to other “at risk”
people. Hopefully, they in turn will also donate. You will save someone’s life!

Here is how you make the donation. From your computer’s browser go to
https://www.unmfund.org/ and enter the name of the fund – “50 ways to save
your heart” and follow the step by step instructions. Alternatively, it can be sent
to the UNM Foundation at 700 Lomas Blvd NE. Albuquerque, NM 87102. Please
reference the name “50 ways to save your heart” when making a gift.

David S. Schade, MD and R. Philip Eaton, MD thank you.
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What Readers Are Saying About This Book

“This book has changed my life. My family and I are making a real change in what
we eat and our exercises to take care of our hearts.” –John Smith, New York

“This information is thought provoking and useful for people in need of help with
health issues.” –Karen Martinez, Texas

“After reading this book I am living healthier. I never knew of all the dangers I was
putting myself in, this book helped me realize I needed to make a change.” –
Michelle Robinson, South Dakota

“Written in a way I can appreciate. Heart disease runs in my family and now I feel
lucky to come across this book so I can understand it.” –Tom Jones, California

“A book made not only to inform but to also heal.” –Scott Burns, Virginia

“Dr. Schade and Dr. Eaton are extraordinary physicians and they’ve created an
invaluable book to anyone who reads it.” –Richard Greene, Arkansas

“Now I know I don’t have to die of a heart attack like my father and my brothers”
– Robert Morton, New Mexico

“The explanations throughout the book are terrific! It helps explain all things cardiac
to patients.” –Judy Ford, Alabama

“A revolutionary plan to prevent heart disease.” –Mary Norris, Nevada

“This book includes more information than how to eat better. It also informs you on
new treatments to keep you healthy.” –Jack Foster, Ohio
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Sandia Mountains overlooking the Rio Grande river
bosque Albuquerque, New Mexico
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